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This dissertation examines the needs of children growing up in families where a 
parent or caregiver is struggling with opioid-related problems. Because of their parents’ 
illness, these children may be at increased risk for exposure to adverse or traumatic 
experiences. Indeed, a growing number of children are coming into contact with 
America’s child welfare systems because of parents’ opioid-related problems. These 
adverse childhood experiences may then increase children’s risk for adult substance use 
disorder, creating a two-generational health problem. However, there are few research 
studies and even fewer policy initiatives focused on meeting the unique needs of these 
families. 
This dissertation seeks to expand knowledge about children in the opioid 
epidemic with three aims: 
1. Identify the number of families where an adult with an opioid use disorder lives with 
a child, and explore these adults’ access to treatment (Chapter 2). 
2. Assess how childhood trauma influences the risk of heroin use at different ages in 
adults who have injected drugs (Chapters 3 & 4). 
3. Test if Florida’s opioid prescribing reforms – designed to prevent overdose deaths – 
also helped reduce children’s contact with the child welfare system (Chapters 5 & 6). 
I address these aims using a combination of public surveys on drug use, 
administrative records on contact with the child welfare system, and primary data 
collection from adults who injected drugs in Baltimore. I show that: 
1. Around 820,00 U.S. adults with an opioid use disorder live with at least one child, but 
fewer than a third report receiving any substance use treatment in the past year. 
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2. Among adults who have injected drugs, a history of very high levels of childhood 
adversity is associated with elevated risk for sustained heroin use into late adulthood. 
3. Florida’s opioid prescribing reforms reduced drug overdose deaths, but did not have 
the added benefit of reducing children’s contact with the child welfare system.  
Findings suggest that existing strategies to address the opioid epidemic are not 
adequately meeting the unique needs of children, and specific, evidence-informed 
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CHAPTER 1. INTRODUCTION  
 2 
1.1. The United States’ Opioid Epidemic 
The United States is currently experiencing its worst-ever epidemic of drug 
related problems, an epidemic primarily attributable to opioids (National Institute on 
Drug Abuse, 2018). 
Opioids are a class of drugs that act on the brain’s opioid receptors to produce 
morphine-like effects (Hemmings & Egan, 2012). Opioids include morphine, prescription 
pain-relievers like Vicodin and OxyContin, illicit drugs like heroin, and powerful 
anesthetics like fentanyl. Some opioids are essential medications for pain management. 
However, improper use – for example, at very high doses or via rapid routes of 
administration that cause high concentrations of the drug to flood the brain – can lead to 
sensations of euphoria (“high”) and, after repeated use, subsequent withdrawal. Both the 
high and withdrawal of opioid use can impair functioning and lead to craving for the 
drug. This makes opioids a class of drug with high potential for addiction (Kolodny et al., 
2015).  
Beginning in the early 1990s, pharmaceutical companies began to aggressively 
promote the idea that chronic pain was an untreated epidemic in the United States. 
Companies, in partnership with professional societies, advocated for more aggressive 
long-term management of chronic, non-cancer pain with opioid pain-relievers. Low-
quality evidence was used to support the claim, now known to be inaccurate, that only a 
small subset of the population is at risk for opioid addiction, and that long-term use of 
these medications was safe for most people (Kolodny et al., 2015). In fact, there are still 
no randomized trials that demonstrate the effectiveness of opioid medications for long-
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term management of chronic pain (Kolodny et al., 2015). Further, sustained opioid use 
rapidly produces physiological changes in the human brain (Younger et al., 2011). 
Despite these concerns, over three decades, there was a dramatic increase in 
opioid pain-reliever prescriptions (Jones, 2013). This was accompanied by a nearly 
parallel increase in adverse health events caused by opioid use (Jones, 2013; Kolodny et 
al., 2015). Between 2001 and 2014, prescription opioid poisoning deaths increased three-
fold, to approximately 18,000 deaths per year. As noted, heroin is also an opioid drug, 
and it is likely many users who can no longer achieve high or access an opioid pain-
reliever prescription transition to heroin. Indeed, in the period from 2002 to 2011, four 
out of five persons who initiated heroin use previously engaged in non-medical opioid 
pain-reliever use (Muhuri, Gfroerer, & Davies, 2013), and by 2014 heroin poisoning 
deaths had increased five-fold to 10,000 per year (National Institute on Drug Abuse, 
2018). Since heroin is commonly injected, it can also increase risk for Hepatitis C and 
HIV. In recent years, extremely potent synthetic opioids like fentanyl have made their 
way into the heroin supply, often without users’ knowledge, increasing users’ risk of 
overdose and death (Miller, Stogner, Miller, & Blough, 2017; National Institute on Drug 
Abuse, 2018). The problem of opioid misuse has now become so severe that, in 2017, 
more than 2 million Americans were living with an opioid use disorder (Ahrnsbrak, Bose, 
Hedden, Lipari, & Park-Lee, 2017) and more than 72,000 people in the United States 
died from a drug overdose (National Institute on Drug Abuse, 2018). For the first time 
since the Centers for Disease Control (CDC) began collecting data on injury deaths, an 
American is more likely to die of poisoning than in a motor vehicle crash (National 
Center for Injury Prevention Control, 2016). 
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Most research on this opioid epidemic has focused on adults. This dissertation 
takes a different approach – it examines both the childhood risk factors that may 
contribute to the onset of opioid misuse, and the subsequent possible impact of a parent’s 
opioid misuse on dependent children.  
1.2. The Pediatric Roots of Opioid-Related Problems 
Early-life risk factors that may influence the initiation and course of harmful 
opioid use have been a neglected area of research. Instead, most research on risk factors 
for opioid use disorder and overdose has focused on prescribing of opioid pain-relievers 
and diversion of opioid pain-relievers for non-medical use (Alexander, Frattaroli, & 
Gielen, 2015; Johnson et al., 2013; Kolodny et al., 2015; Muhuri et al., 2013). As the toll 
of illicit drugs like heroin and fentanyl has increased in recent years, there is also a 
growing research emphasis on expanding access to overdose prevention drugs like 
naloxone and medication-assisted addiction treatments (Alexander et al., 2015; Volkow, 
Frieden, Hyde, & Cha, 2014). This focus is consistent with a research agenda prioritizing 
proximal risk factors and treatment targets that can prevent overdose deaths and remedy 
an immediate overdose crisis. However, understanding the role of early-life risks of 
opioid-related problems is also important for two reasons: 1) Understanding how early 
life risks for opioid-related problems influence the onset of opioid misuse can help 
prevent the initiation of misuse by younger generations; 2) Understanding how early-life 
risks influence the course of opioid misuse can help improve the quality of treatment for 
the many Americans already suffering from an opioid use disorder. 
1.2.1 Childhood Adversity and Adult Health 
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There are good reasons to believe that early life risk factors may influence the 
onset and course of opioid use disorder. There is strong evidence that exposure to 
maltreatment, household dysfunction, or other forms of adversity in childhood can 
increase risk for a wide range of mental, behavioral, and physical problems, including 
many of the leading causes of death (Anda et al., 2006; Felitti et al., 1998). Evidence 
from both observational studies in humans and randomized trials in animals show that 
trauma and deprivation in childhood lead to changes in adult brain regions and systems 
linked to addiction and psychopathology (Enoch, 2011). Exposure to childhood abuse or 
household dysfunction is a risk factor for substance use problems later in life (Dube et al., 
2003), including use of “street drugs,” earlier initiation of drug use and self-identified 
addiction to drugs. A history of child sexual abuse is associated with earlier initiation of 
injection drug use (Ompad et al., 2005). Children of adults with an alcohol use disorder 
are at elevated risk for alcohol use disorder, and there is some evidence this effect is 
partly mediated by children’s exposure to adversity (Anda et al., 2006). This evidence 
suggests a history of trauma may be an important risk factor for opioid use disorder as 
well. 
1.2.2 Childhood Trauma and Opioids 
In fact, childhood trauma has been identified as a risk factor for an opioid use 
disorder specifically (Naqavi, Mohammadi, Salari, & Nakhaee, 2011). As compared to 
persons seeking treatment for nicotine or alcohol, persons seeking opioid treatment were 
more likely to have experienced a childhood trauma, and experienced trauma at an earlier 
age on average (Naqavi et al., 2011). One matched case control study found a history of 
child sexual abuse to be a risk factor for opioid use disorder among women, and a history 
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of physical and emotional abuse to be risk factors among men (Conroy, Degenhardt, 
Mattick, & Nelson, 2009). Indeed, some authors have argued that a history of childhood 
trauma plays a central role in the etiology of heroin use disorder (Darke, 2013).  
Moreover, childhood adversity is a common antecedent for two other proximal 
risk factors for opioid-related problems. Specifically, childhood abuse and household 
dysfunction are associated with increased risk for both chronic pain (Davis, Luecken, & 
Zautra, 2005) and use of a greater number of prescription medications and medication 
classes (Anda, Brown, Felitti, Dube, & Giles, 2008).  
Taken together, these findings suggest an important role for childhood adversity 
in the onset and course of opioid-related problems. A better understanding of this 
relationship may help improve prevention and treatment efforts. 
1.3. Collateral Pediatric Consequences of the Opioid Epidemic 
In addition to the pediatric causes of opioid-related problems, more research is 
needed to understand the pediatric consequences of the current opioid epidemic. While 
most public health responses to opioids target adult overdose (Alexander et al., 2015), 
with more than a million Americans over age 12 suffering from an opioid pain-reliever or 
heroin use disorder (Ahrnsbrak et al., 2017), the consequences of adult opioid use are 
likely spilling over and impacting children. In fact, in addition to increased adolescent 
use of opioid drugs (Ryan et al., 2016), there are at least four pathways by which 
increasing rates of opioid use by adults may be imposing collateral consequences on 
children and youth: 1) maternal opioid use during pregnancy and its teratogenic effects, 
2) maladaptive parent-child interaction and insecure attachment resulting from the 
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effects of opioids on the brain, 3) material deprivation resulting from money and time 
spent on drugs, and 4) extended separation from parents.  
1.3.1 Opioid Use During Pregnancy  
While the teratogenic effects of opioids are less severe than those of alcohol and 
tobacco, opioid use during pregnancy can have harmful effects on the developing fetus 
(European Monitoring Center for Drugs and Drug Addiction, 2012). Specifically, opioid 
use during pregnancy is associated with low birth weight, premature birth, impaired 
intrauterine growth, and respiratory depression. If a fetus becomes physiologically 
dependent on opioids in the womb, it may experience the symptoms of opioid withdrawal 
including fever, excessive crying, irritability, and difficulty feeding; this is known as 
neonatal abstinence syndrome. If a mother injects opioids, this increases risk for blood-
borne illness like HIV and Hepatitis C (HCV), which may be transmitted to the fetus. 
Further, opioid use during pregnancy has increased during the current opioid epidemic. 
Between 2000 and 2009, the rate of antepartum opioid use in the United States increased 
five-fold. Concomitantly, rates of neonatal abstinence syndrome increased three-fold 
(Patrick et al., 2012). This is probably the pediatric consequence of the opioid epidemic 
that has received the most attention from researchers (Patrick & Schiff, 2017).  
1.3.2 Maladaptive Parent-Child Interaction.  
Most drugs with high potential for substance use disorder act at least in part on 
the oxytocin and dopamine receptors that stimulate the reward and pleasure centers or the 
brain, and opioids are no exception (Renk et al., 2015). Importantly, there is evidence that 
these same pleasure-inducing systems play an important role in interpersonal bonding. In 
fact, evidence from animal models suggests that the impaired social bonding associated 
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with drug use is mediated by the action of these drugs on these pleasure centers in the 
brain (Renk et al., 2015; Young, Liu, Gobrogge, Wang, & Wang, 2014). This evidence 
suggests that opioid use may impair parents’ ability to adaptively interact with their 
children, increasing their children’s risk for insecure attachment (Renk et al., 2015), 
which is associated with long term negative effects on  interpersonal interaction and adult 
psychopathology (Lyons-Ruth, Bureau, Easterbrooks, Obsuth, & Hennighausen, 2013; 
Mikulincer & Shaver, 2012). 
Further, parent substance use generally is associated with decreased attentiveness 
to children’s needs and more authoritarian parenting styles (Mayes et al., 1997; Wellisch 
& Steinberg, 1980). Both qualitative and quantitative studies of children with mothers in 
methadone maintenance have found that parents with opioid use disorder are 
disproportionately likely to engage in coercive parenting and high-risk behavior for child 
abuse perpetration (Barnard & McKeganey, 2004; Dawe & Harnett, 2007). Parent 
substance use is also associated with deficits in emotion regulation and parenting 
knowledge (Neger & Prinz, 2015). While these characteristics may not be caused by drug 
use, but instead may be a comorbid outcome of a history of life trauma (Patrick & Schiff, 
2017), all of these behaviors found to be more prevalent in parents with substance use 
problems are risk factors for child abuse. 
Finally, if parents are unable to adequately bond with, or supervise their children, 
this may increase risk for intentional or unintentional injury. Zip codes with higher rates 
of opioid overdoses also have higher rates of intentional and unintentional child injury, 
even after controlling for sociodemographic confounders (Wolf, Ponicki, Kepple, & 
Gaidus, 2016), and counties with higher rates of opioid-related problems also have higher 
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rates of substantiated child abuse (Ghertner, Baldwin, Crouse, Radel, & Waters, 2018). 
This is consistent with the shared epidemiology of child neglect and childhood injury 
(Peterson & Brown, 1994). It is also consistent with qualitative studies of parents in 
recovery from heroin use disorder, who describe behaviors that increase risk for 
unintentional injury – such as failing to supervise children – and intentional injury – such 
as failing to protect children from abuse by intimate partners (McKeganey, Barnard, & 
McIntosh, 2002). 
1.3.3 Material Deprivation.  
Substance use disorders are extremely costly to the user. Qualitative studies of 
mothers in treatment for heroin use paint a picture of parents strapped for the time and 
money needed to adequately care for children. In one qualitative study, parents in 
recovery from heroin use disorder reported that, during the time when they were using, 
they spent money on drugs instead of on food or clothing for children, failed to establish 
regular household routines, and experienced extended periods of separation from their 
children (McKeganey et al., 2002). Quantitative findings are similarly bleak. One study 
of 100 daily, untreated heroin users in Detroit found that participants spent an 
extraordinary 72 percent of their income on heroin and another 11 percent on cigarettes 
and alcohol, with only 12 percent dedicated to food and shelter (Roddy & Greenwald, 
2009). All of this suggests that many children of parents with an opioid use disorder may 
suffer from the adverse effects of growing up in poverty.  
1.3.4 Extended Separation 
Finally, a parent’s opioid use disorder can lead to extended periods of parent child 
separation. An early study of mothers participating in methadone treatment found that 80 
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percent were arrested at least once during the time the child was growing up and 14 
percent were hospitalized for an emotional disorder (Kolar, Brown, Haertzen, & 
Michaelson, 1994), experiences that could lead to extended periods of separation between 
parent and child. Further, if parents struggling with opioid use disorder are unable to 
adequately care for their children, this can lead to children being placed in foster care. 
While precise estimates vary, studies have consistently found a high prevalence of 
substance use problems among families involved with the child welfare system (Barth, 
2009; Traube, 2012), particularly among infants (Wulczyn, Ernst, & Fisher, 2011). More 
recent research has specifically linked escalating rates of opioid-related problems to 
increases in the number of children entering foster care (Ghertner et al., 2018), and child 
welfare agencies across the country report that there are children entering and remaining 
into foster care for extended periods of time because of parent opioid use problems 
(Radel, Baldwin, Crouse, Ghertner, & Waters, 2018b). 
1.4 A Two-Generational Problem 
In summary, the research presented suggests that the opioid epidemic poses 
numerous threats to children, and that existing prevention, child protection, social 
insurance, and treatment services are not adequate to address these threats. Thus, the 
epidemic is likely increasing the number of children exposed to “polyvictimization” and 
“complex trauma” (Finkelhor, Ormrod, Turner, & Hamby, 2005) – exposure to a large 
number of diverse, chronic, adverse experiences spread over the course of childhood. As 
already discussed, these experiences are associated with increased long term risk for a 
wide range of antisocial behaviors, unhealthy behaviors, mental disorders, chronic 
diseases, and suicide (Finkelhor et al., 2005), along with, most pertinently, the onset of 
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opioid use disorder. Thus, if the pediatric implications of the current opioid epidemic 
remain under-addressed, long-term behavioral health consequences are likely to persist 
even if efforts to prevent adult overdose are successful. In this way, the current opioid 
epidemic lays the groundwork for a future epidemic of opioid-related or other health 
problems. 
1.5. Solutions and Barriers 
Adequately meeting the needs of families struggling with opioid-related problems 
and interrupting the intergenerational health threats described above requires 
collaboration between three systems – behavioral health and substance use treatment 
systems, child welfare systems, and the courts (Feder, Letourneau, & Brook, 2018). 
Unfortunately, collaboration between these systems is often poor and misinformation 
about best practices in one system will abound in the others (Feder et al., 2018; Stedt & 
DeCerchio, 2016).  
1.5.1 Behavioral Health and Substance Use Treatment. 
Behavioral health systems are responsible for providing parents and pregnant 
women with opioid-related problems with the evidence-based treatments they need to 
avoid overdose, regain agency over their lives, and adequately care for their children.  
The best supported treatments for opioid use disorder are “medication-assisted” – 
they supplement traditional counseling and behavioral therapies with medications like 
methadone and buprenorphine to ameliorate the neurologic changes induced by extended 
opioid use. These medications prevents the agonizing symptoms of opioid withdrawal, 
reduce the risk of relapse to illicit use, and improve functioning (Connery, 2015; Volkow 
et al., 2014). 
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The benefits of medication-assisted treatment have been specifically studied and 
demonstrated in pregnant women (Wong et al., 2011), for whom medication maintenance 
increases participation in prenatal care, reduces risk of harm to the mother and fetus, and 
is clearly preferred to detoxification without medication in nearly all cases (Heberlein, 
Leggio, Stichtenoth, & Thomas, 2012; Patrick & Schiff, 2017). Further, new research 
offers evidence that when parents involved with the child welfare system receive 
medication-assisted treatment, they are reunified with their children more rapidly (Hall, 
Wilfong, Huebner, Posze, & Willauer, 2016; Radel, Baldwin, Crouse, Ghertner, & 
Waters, 2018a).  
It is also essential to have a holistic approach to care prepared to meet the 
challenging psychosocial comorbidities that often accompany opioid use, and, in the case 
of pregnant women, to treat neonatal abstinence symptoms after birth (Winklbaur et al., 
2008). Women are more likely to remain in treatment if childcare is provided onsite, and 
if providers engage in trauma-informed practice (Patrick & Schiff, 2017).  
In summary, medication-assisted treatment supplemented by specialty services for 
parents and pregnant women are a cornerstone of meeting the needs of children growing 
in families struggling with opioid-related problem.  
Unfortunately, medication-assisted treatment for opioid use disorder is both 
unavailable and underused in the general population, with a likely a gap of nearly one 
million people nationally who could benefit from methadone or buprenorphine treatment 
but do not receive any (Jones, 2013). There are likely particularly severe access problems 
for pregnant women and child welfare involved parents (Patrick & Schiff, 2017; Radel et 
al., 2018a). Only 19 states have even a single substance use treatment program 
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specializing in pregnant women, and only 15 percent of substance use treatment centers 
offer specialty services for pregnant women. There is a particular shortage of treatment 
for pregnant women in rural areas (Patrick & Schiff, 2017; Radel et al., 2018a), where 
illicit opioid use has increased fastest. Further, as discussed below, misconceptions 
regarding and stigma toward medication-assisted treatment may deter parents from 
receiving appropriate care (Radel et al., 2018a). 
1.5.2 Child Welfare 
Child welfare services provide an important complement to treatment for parents, 
ensuring the unique needs of children are met while their parents receive treatment, as 
well as facilitating access to or providing other services to help the family unit heal. First 
among those other services is substance use treatment, and child welfare agencies can and 
should facilitate access to medication-assisted treatment for parents (Radel et al., 2018a).  
However, child welfare agencies also play an important role in providing 
parenting and family support services. There are a number of parenting interventions that 
either explicitly target or have been adapted to parents with substance use disorders 
(Neger & Prinz, 2015). One review of programs appearing in scientific literature found 
that programs tend to be effective when the parenting intervention is started immediately 
alongside initiation of substance use treatment, when significant others are included as 
key partners in treatment, and when transportation and lack of childcare are not barriers 
to treatment (Neger & Prinz, 2015). Most evidence-based programs rely on some 
combination of cognitive-behaviorally informed parenting intervention, relapse 
prevention techniques to address substance use, and efforts to facilitate access to needed 
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social and medical services (Grant, Ernst, Streissguth, & Stark, 2005; Haggerty, Skinner, 
Fleming, Gainey, & Catalano, 2008; Renk et al., 2015).  
Unfortunately, substance use treatment and child welfare fields remain balkanized 
(Staton-Tindall, Sprang, Clark, Walker, & Craig, 2013). Just as substance use treatment 
programs may not be adequately equipped to accommodate the special needs of parents 
and pregnant women, child welfare agencies are often ill-informed about best practices 
for treating substance use disorders. In particular, misperceptions of medication-assisted 
treatment abound among child welfare workers, which may prevent parents from being 
referred to program that offer the most effective care (Radel et al., 2018a). Additionally, 
child welfare agencies may operate on constricted legally-imposed timelines requiring 
reunification or termination of parental rights by particular deadlines; these timelines may 
not be consistent with the normal course of opioid use disorder treatment, which can take 
many years, can be characterized by periods of relapse and remission, and often involves 
indefinite maintenance on medication. 
1.5.3 Courts 
 Finally, courts have enormous decision-making authority for both adults who use 
substances illicitly and adults involved with the child welfare system. Informed legal 
decision making and well-structured court programs can facilitate access to substance use 
treatment programs, expedite the child welfare process, and help overcome the systemic 
divide between behavioral health and child welfare described above. This has been 
demonstrated by family drug courts – specialized dockets that divert drug-using parents 
into treatment – that have been shown to increase treatment retention and reduce foster 
care time (Marlowe & Carey, 2012; Stedt & DeCerchio, 2016). Conversely, when courts 
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are ill-informed, they may order decisions that are not in the best interest of the child, 
such as requiring parents to terminate medication-assisted treatment, or terminating 
parental rights solely because of an episode of relapse into illicit use. 
1.6 Summary and Motivation for Research 
In summary: 
1. A growing number of children are likely at risk for adversity, trauma, and 
child welfare involvement as a result of the opioid epidemic. 
2. This exposure to adversity and trauma resulting from parent substance use 
may in turn increase these children’s risk for adult health problems, including 
opioid misuse, creating a two-generational health burden. 
3. There are policies and services that may help families heal from or avert these 
health harms, but poor coordination between substance use, child welfare, and 
justice systems may impede parents access to these services. 
If these challenges are not addressed, increases in the prevalence of childhood adversity 
resulting from the opioid epidemic could transform a short-term public health crisis into a 
long-term burden on population health.  
 The remainder of this dissertation examines a number of important questions 
about children in the opioid epidemic. Aim 1 (Chapter 2) makes the first estimate of the 
number of households with children where an adult has an opioid use disorder. It then 
examines the prevalence of substance use treatment utilization among the adults in these 
household. Finally, it examines if these adults living with children face unique barriers to 
care that are less common among their counterparts without children. Aim 2 examines 
how childhood adversity can influence the course of adult opioid misuse. A pre-analysis 
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(Chapter 3) explores heterogeneity in common trajectories of heroin use over the life 
course. Then, in the main analysis (Chapter 4), self-reported childhood adversity is 
examined as a predictor of a more severe trajectory of substance use. Finally, Aim 3 
examines one important policy effort designed to combat the opioid epidemic – Florida’s 
initiative to reduce irresponsible opioid prescribing through the introduction of a 
Prescription Drug Monitoring Program (PDMP) and a crackdown on negligent 
independent pain management clinics (“pill mills”). In a pre-analysis, (Chapter 5) a new 
method – Bayesian structural time series (BSTS) – is presented for evaluating the impact 
of new state policies. Then, BSTS is validated for the present study by replicating a 
published positive finding that the aforementioned prescribing reforms prevented 
overdose deaths. Finally (Chapter 6), BSTS is used again to determine if Florida’s 
intervention had the ancillary benefit of preventing contact with the child welfare system. 
 Collectively, these research projects provide important new information that can 
help policy makers 1) address the needs of adults with opioid use disorder who have a 
history of childhood trauma, and 2) prevent the transmission of that trauma to a future 
generation of children through evidence-informed services and policies that meet the 
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CHAPTER 2. U.S. ADULTS WITH OPIOID USE DISORDER LIVING WITH 





Background: U.S. adults with an opioid use disorder who live with a child have 
unique treatment needs, but little is known about the treatment use of these adults. 
Methods: Data come from the 2010-2014 versions of the National Survey on 
Drug Use and Health, an annual survey assessing substance use in the United States. 
Adults (>=18) with a heroin or pain-reliever use disorder living in a household with a 
child (<18) were compared to adults not living with children on their use of substance use 
treatment, treatment settings, payment sources, perceived unmet need for treatment, and 
barriers to care using logistic regression to adjust for demographic differences between 
groups.  
 Results: Of the approximately 820,000 adults with an opioid use disorder living 
with at least one child, 28% reported receiving any past-year substance use treatment, a 
rate comparable to adults not living with a child (30%). Among adults reporting unmet 
treatment need, those who lived with a child were more likely to report that access 
barriers like not being able to find the right kind of program (aOR 2.9, 95% CI 1.2 – 7.1), 
as well as stigma (aOR 4.1, 95% CI 1.5 to 11.2), kept them from receiving care.  
 Conclusion: The majority of adults with OUD do not receive care. Adults with 




 The United States is currently experiencing its worst ever epidemic of drug-
related problems, an epidemic driven primarily by opioids. With at least 2 million 
Americans suffering from an opioid use disorder, as discussed in the introductory 
chapter, there is growing evidence that this epidemic of adult opioid use is spilling over 
and increasing the risk that children will be exposed to toxic stress, trauma and other 
negative consequences as a result of parental use. Research shows that experiences of 
trauma and deprivation in childhood are robust risk factors for a host of chronic health 
conditions across the life course (Anda et al., 2006; Felitti et al., 1998; Lamont, 2010), 
including adult substance use problems (Dube et al., 2003). Without an adequate public 
response to meet the needs of these children and their families, there is a risk that today’s 
acute opioid crisis will evolve into a longer term, chronic health burden for the next 
generation related to increased likelihood of adverse exposures described in the 
Introduction.  
 An essential strategy for meeting the needs of children affected by the opioid 
epidemic is ensuring their parents and caregivers have access to evidence-based 
treatment. Among families involved in the child welfare system, facilitating parents’ 
access to medication-assisted treatment for opioid use improves the safety and 
developmental appropriateness of parent-child interactions, and is associated with 
increased odds of parent-child reunification following a foster care placement (Hall, 
Wilfong, Huebner, Posze, & Willauer, 2016). 
 Unfortunately, fewer than one-third of Americans with opioid use disorder 
receive any treatment, and fewer than a third of those in treatment receive medication-
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assisted treatment (Feder et al., 2017; Krawczyk, Feder, Fingerhood, & Saloner, 2017). A 
number of factors may contribute to this need-treatment gap including a lack of perceived 
need for treatment (Ali, Teich, & Mutter, 2015), inability to pay for treatment (Feder et 
al., 2017), a shortage of providers (Jones, Campopiano, Baldwin, & McCance-Katz, 
2015), and stigma associated with seeking care.  
There are reasons to believe that the treatment patterns and barriers faced by 
parents with dependent children are different from those of childless adults or adults 
whose children are grown or no longer in their care. In his classic healthcare utilization 
model, Andersen describes three sets of factors that can influence utilization of 
healthcare: 1) predisposing characteristics such as demographics, 2) real or perceived 
need for care, and 3) enabling resources or barriers to care (Andersen, 1995). Parents and 
caregivers with opioid use disorders may differ from their counterparts without 
dependent children on all three of these factors: 1) Parents and caregivers may be 
demographically different from adults without dependent children; 2) The desire to be a 
good parent or “be there” for children may influence perceived need for treatment, and 
has been reported in qualitative studies as a reason parents choose to seek care (Barnard 
& McKeganey, 2004). 3) Parents and caregivers may face unique barriers to care – for 
example, a shortage of family-friendly treatment programs or a lack of childcare; and 
parents and caregivers may also have unique enabling factors – for example, increased 
likelihood of Medicaid eligibility due to higher income eligibility limits for parents in 
some states. Understanding the current service access and utilization of adults with opioid 
use disorder who have children – and how these adults differ from adults without 
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dependent children – can inform a public health response to the opioid epidemic that 
addresses the epidemic’s effects on children and families.  
This paper uses data from a nationally representative survey to describe the 
substance use treatment access and utilization of adults who have an opioid use disorder 
and are living with children under age 18, and compare these adults living with children 
to their counterparts not living with children under age 18. It seeks to answer the 
following questions: 
1. What proportion of adults living with children have an opioid use disorder?  
What are the demographic characteristics of this population? 
2. What proportion of adults with an opioid use disorder who live with children 
receive substance use treatment? In what settings do they receive treatment and 
who pays for their care?   
3. What proportion of adults with an opioid use disorder who live with children 
perceive a need for substance use treatment? What barriers do these adults face in 
receiving care? 
In all cases, these characteristics are compared to adults with opioid use disorder who are 
not living with children, to better understand the unique treatment landscape facing adults 
with an opioid use disorder who live with children. 
2.2 Materials and Methods 
2.2.1. Study Population and Data 
 The National Survey on Drug Use and Health (NSDUH) is an annual, nationally 
representative survey of the U.S. households conducted by the Substance Abuse and 
Mental Health Services Administration (SAMHSA). Respondents are asked about their 
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use of alcohol, tobacco, and other drugs; about the use of substance use treatment; and 
about an array of experiences and conditions thought to be related to substance use, 
including substance use disorders, mental health problems, and physical health problems. 
Data for this study are drawn from the 2010-2014 NSDUHs. Beginning in 2015, the 
NSDUH prescription drug module was revised to begin identifying people who used 
prescription drugs as directed by a doctor; this broadened the pool of respondents 
assessed for a pain-reliever use disorder. For this reason, 2010-2014 was selected as the 
most recent consecutive five-year period in which survey questions were comparable 
across the full period (Quast, Storch, & Yampolskaya, 2018; Wolf, Ponicki, Kepple, & 
Gaidus, 2016). SAMHSA provides a cleaned and anonymized version of the dataset 
online for public use through its Substance Abuse and Mental Health Data Archive 
(SAMHDA) (SAMHSA, n.d.).  
 The study population was comprised of adults (18 or older) who met criteria for 
an opioid use disorder in the year preceding their interview. This included participants 
who reported using a pain-reliever in a manner other than prescribed by a doctor, as well 
participants who reported heroin use.  Use disorder was defined as meeting criteria for 
DSM-IV substance abuse or dependence. Because all variables used in the analysis were 
statistically imputed by SAMHSA prior to making data publicly available, there are no 
missing observations. The final population consisted of 3,287 adults with opioid use 
disorder. Some sub-analyses were completed on the sub-population of adults who 
received treatment (n = 923), and the subpopulation who reported a perceived unmet need 
for treatment (n = 408).  
2.2.2 Measures 
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 2.2.2.1 Exposure. The exposure of interest in the present study is the presence of 
at least one child (17 or younger) living in the household of the survey respondent at the 
time of the survey. Note that the NSDUH does not provide information about whether the 
adult respondent has any custodial responsibility for, or biological relationship to, any 
children in the household. 
 2.2.2.2 Study outcomes. The primary outcome was self-reported past-year use of 
any treatment for drugs or alcohol. Among those who reported receipt of any treatment, 
we examined treatment in specific settings: hospital, inpatient specialty program, 
outpatient specialty program, mental health center, emergency department, physician’s 
office, jail or prison, and self-help group. Among those who reported receipt of any 
treatment, we also examined the reported payment source: insurance, savings, a family 
member or friend, or a court.  
 The second outcome of interest was perceived unmet need for treatment. This 
includes respondents who did not receive any treatment but reported they felt a need for 
treatment (for use of any substance), as well as respondents receiving treatment who 
reported they felt a need for additional treatment. Among those who reported a need for 
treatment, following Ali and colleagues (Ali, Teich, & Mutter, 2016) we examined five 
reasons for not receiving treatment: 1) Financial barriers included having no insurance or 
insurance not covering treatment; 2) Access barriers included having no transportation, 
not being able to find the right type of program, not being able to find a program with 
openings, or not knowing where to go; 3) Stigma included fearing that that others would 
know about drug use, that neighbors would have a negative opinion, or that treatment 
would have a negative effect on one’s job; 4) Not being a priority included a report of not 
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needing help, not thinking treatment would help, or participants believing they could 
“handle it” without treatment; 5) A final reason was “not ready to stop using.” The 
available items do not inquire about parent-specific barriers, such as inadequate childcare 
or fear of having dependent children removed from care. 
 2.2.2.3 Demographics. Demographic variables examined include age, sex, 
race/ethnicity, education level, employment status, urbanicity of residence, past-year 
presence of an alcohol use disorder, and past-year use of tobacco.  
2.2.3. Analytic Approach 
 As a preliminary analysis, we present trends over time in use of substance use 
treatment and perceived need for substance use treatment, stratified by the presence of a 
child in the household. Then, adults living with children and adults living without 
children were compared on all outcomes using logistic regression. Unadjusted models 
were estimated, as well as models that adjusted for all demographic variables. Finally, 
past research on substance use treatment for adults with children has mostly focused on 
women (Greenfield et al., 2007), but the effect of the presence of a child on treatment use 
and need for treatment may differ by sex. We test this hypothesis explicitly by adding an 
interaction term between presence of a child in the household and sex in models for these 
two outcomes. Regression coefficients were, in all cases, exponentiated for interpretation 
as odds ratios – the relative odds of the outcome among adults living with children as 
compared to adults not living with children.  
 All estimates incorporated survey design elements – clustering, stratification, and 
weighting – and therefore can be considered representative of the United States 
population living in households during the 2010-2014 period. Standard errors and 
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corresponding 95% confidence Wald confidence intervals were estimated using Taylor 
series linearization. All analyses were conducted in R 3.4.3 (R Core Team, 2017) using 
the “survey” package (Lumley, 2004). 
 As a sensitivity analysis, we restricted the sample to adults 26 and older – who 
may be more likely to have caregiving responsibilities for children living in their 
household – and repeated the entire analysis.   
2.3 Results 
 2.3.1 Demographics 
Based on the nationally representative NSDUH data, we estimate that during the 
period from 2010 – 2014, approximately 2 million U.S. adults – just under 1 percent of 
all adults – met criteria for an opioid use disorder. Of these, approximately 820,000 
(~41%) were living with at least one child. In the population with opioid use disorder, the 
demographics of adults living with children and adults living without children were 
somewhat different – adults with children were more likely to be between the ages of 26 
and 50 than younger or older age groups, to be female, to have lower levels of education, 
and to live outside urban centers, and were less likely to have an alcohol use disorder. 
Detailed demographics are shown in Table 1.  
2.3.2 Treatment 
Among adults with an opioid use disorder living with children, an estimated 27.7 
percent (95% CI 23.5% to 31.9 percent) reported receiving any substance use treatment 
in the past year. This rate was not significantly different from adults not living with a 
child (aOR: 0.91, 95% CI 0.79 to 1.18). Interaction tests suggest this null effect was the 
same for men and women (analysis not shown). There were no discernible trends over 
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time in the prevalence of treatment use, nor did trends differ between adults with children 
or adults without children (Figure 1). 
Among those who were treated, the most common treatment settings were 
outpatient specialty treatment (60.2%, 95% CI 52.3% to 68.1%) and self-help groups 
(58.4%, 95% CI 51.5% to 65.4%). The most common source of financing for treatment 
was personal savings. The prevalence of treatment, treatment settings, and payers were 
similar between adults with children in the household and adults without children in the 
household, and there were no significant differences between groups in adjusted or 
unadjusted analyses.  
 2.3.3 Perceived Need for Treatment  
About 14.8% (95% CI 10.8% to 18.9%) of adults living with a child reported a 
perceived unmet need for treatment or for additional treatment. There were no significant 
differences in perceived need between adults living with children and adults living with 
no children (aOR 1.17, 95% CI 0.73 to 1.88). Interaction tests suggest this null effect was 
the same for men and women (analysis not shown). There were no discernible trends over 
time in the prevalence of perceived need, nor did trends differ between adults with 
children or adults without children (Figure 1).  
Among those with a perceived unmet need for treatment, by far the most 
commonly reported barrier to care was financial (60.8%, 95% CI 47.0% to 74.6%) – this 
was true for both adults with children and adults without children. Among those with 
perceived need, there were significant differences in barriers to care. After adjusting for 
all measured demographic factors, stigma (aOR 4.09, 95% CI 1.50 to 11.17), access 
barriers (aOR 2.90, 95% CI 1.19 to 7.07), and not believing that treatment should be a 
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priority (aOR 2.79, 95% CI 1.17 to 6.62) were all more common among adults living 
with children than among adults living without children. By contrast, adults living with 
children were less likely to report that they would not get treatment because they were 
“not ready to stop using” (aOR 0.39, 95% CI 0.19 - 0.8). 
 Detailed results are shown in Table 2. Results of the sensitivity analysis were 
qualitatively unchanged from the main analysis and are not shown.  
2.4 Discussion 
As recently as 2010-2014, approximately four in ten U.S. adults with an opioid use 
disorder – more than 800,000 people – lived in a household with a child. Not all of these 
adults are parents or would have custodial responsibilities (and that data is not available 
in the public access NSDUH). Nevertheless, it is likely that many are parents or 
caregivers. Even in cases where these adults do not have formal parental or caregiver 
relationships with children in their households, there are still pathways by which the 
presence of an adult with an opioid use disorder in the household could increase 
children’s risk of harm, for example if drugs or drug paraphernalia are left unsecured 
(Kennedy-Hendricks et al., 2016), or if the participant introduces high risk partners into 
the social ecology of children (Barnard & McKeganey, 2004). This estimate does not 
even capture parents whose children have been removed and placed in foster care, nor 
does it capture parents in inpatient or correctional settings. In summary, there is good 
reason to believe that the opioid epidemic is affecting hundreds of thousands of families 
and their children. 
Moreover, adults with opioid use disorder living with children are demographically 
different from their counterparts living without children. Adults with opioid use disorders 
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who live with children are more likely to be women than their counterparts. Historically, 
women have been less likely to seek substance use treatment than men, and may have a 
different risk profile – including comorbid psychiatric disorders and a history of trauma – 
which would make them candidates for treatment in specialized settings (Greenfield et 
al., 2007). Adults with opioid use disorder who live with children are also more likely to 
live in rural areas where medication-assisted treatment for opioid use disorder is scarce, 
particularly special programs for pregnant or parenting women (Patrick & Schiff, 2017). 
We found that fewer than three in ten adults with an opioid use disorder living with 
children reported receiving any form of treatment, suggesting a major unmet need for 
substance use treatment for families, comparable to that for adults living in households 
without children. Unfortunately, NSDUH offers no way of assessing the quality of 
treatments. Among those treated, the most common source of payment for treatment was 
personal savings. Again, this was true regardless of the presence of children in the 
household.  Of note, patterns in treatment financing may have changed following the 
expansion of Medicaid under the 2014 Affordable Care Act, which substantially reduced 
the uninsured rate among adults with heroin use disorder and tripled the odds of treatment 
being paid for by insurance (Feder et al., 2017). In fact, Medicaid is the primary form of 
insurance coverage for adults with opioid use disorder (Feder et al., 2017), and other 
research suggests that acquiring Medicaid is associated with reduced unmet need for 
substance use disorder treatment (Wen, Druss, & Cummings, 2015); preserving and 
expanding Medicaid coverage is likely essential to expanding access to opioid use 
disorder treatment for families.  
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Contrary to our hypothesis, we found no difference in perceived unmet need for 
treatment between adults living with children and adults living without children. 
However, among those who perceived a need for treatment, there was some evidence that 
adults living with children were less likely to say they were “not ready to stop using.” 
This is consistent with Barnard and colleagues’ conclusion that living with a child is a 
motivator for adults to reduce or stop using illicit opioids (Barnard & McKeganey, 2004). 
Barnard and colleagues’ research was conducted retrospectively in a sample that had 
received treatment. Taken together, our findings and their findings are consistent with the 
notion that living with a child is a motivation for people who have an opioid use disorder 
to try to change their behavior, but only among the minority who are aware that their 
opioid use is problematic. 
Further, among those who perceived unmet treatment need, we also found that 
stigma was twice as likely to be reported as a barrier to treatment among adults living 
with children, and this effect rose to four times more likely after adjusting for 
demographic factors. Adults with children may fear that they will be judged by neighbors 
or peers to be bad parents if their substance use disorder is found out, or that their 
children will be removed from their care if they seek treatment for substance use 
disorders. Indeed, media representations of parents struggling with opioid addiction can 
be stigmatizing when taken out of context (Carissimo, 2016). Access barriers were also 
twice as common among adults living with children. This is consistent with other 
research which has found that access to transportation, availability of childcare, and 
trauma-informed programming play an important role in engaging parents and pregnant 
women in treatment (Neger & Prinz, 2015; Patrick & Schiff, 2017), although these 
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specific barriers were not assessed in the NSDUH survey. It is important to note that 
these between-group comparisons were estimated in a small sample of only 408 adults; 
the very wide confidence intervals suggest that these results be interpreted as preliminary. 
It is also important to note that financial barriers were the most important barrier to 
treatment for adults living with and without children. Addressing financial barriers is 
probably the most important strategy for increasing utilization of substance use treatment 
for both groups.  
This study has a number of limitations. First, there is evidence that, prior to 2015, the 
NSDUH undercounted opioid use disorders among people who were taking opioids long-
term as prescribed by a doctor. This is a significant limitation, because there is some 
evidence that as many as a third of this population would meet criteria for a use disorder, 
and risk for overdose in this population is still high (Boscarino et al., 2011; Kolodny et 
al., 2015). Second, the NSDUH only captures individuals in households; people who use 
opioids illicitly are likely overrepresented in marginalized populations such as homeless 
or incarcerated persons who will not be captured in the NSDUH. Therefore, any trends 
we identify should be understood to be representative only of the population living in 
households. Third, data from 2010-2014 may not be representative of the current state of 
the opioid epidemic, which has grown more severe even in the last few years (National 
Institute on Drug Abuse, 2017). Fourth, this study focuses on adults living with a child in 
the household. These adults may or may not be parents, nor do they necessarily have 
caregiving responsibilities. Conversely, those adults who are not living with a child in the 
household may be parents or caregivers to children who do not live in the household, for 
example if their children have been placed in foster care or have simply moved out. Our 
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sensitivity analysis restricted to adults over 25 – who may be more likely to have 
caregiving responsibilities – did not change the results. However, future research should 
examine the needs of parents and caregivers specifically. Fifth, lack of detail in the 
NSDUH’s measures of treatment and treatment barriers to care make findings difficult to 
interpret. In particular, there is no way to know what percentage of treatment is 
medication-assisted – the highest standard of care for opioid use disorder – and important 
barriers to substance use treatment for parents such as lack of childcare were not 
assessed.  Finally, the data used in this analysis are cross-sectional which limits causal 
inference regarding the association between living with children and self-reported 
barriers to care 
2.5 Conclusion 
This study is the first to examine, on a national scale, the treatment needs of adults 
struggling with opioid use disorder while living with minor children. We show that more 
than four out of every ten adults with an opioid use disorder are living with children, and 
that most of these adults are not receiving any treatment in a one-year period. Expanding 
access to treatment – in particular, medication-assisted treatment – for all people with 
opioid use disorder has been identified as an essential strategy for addressing the current 
epidemic (National Institute on Drug Abuse, 2017). Yet, for the most part, the needs of 
children and families in the opioid epidemic have not been a focus of research or policy. 
For example, in a recent New York Times survey of how 30 drug policy experts would 
prioritize investments in combatting the opioid epidemic, there was no mention of 
specialized services for children or families (Katz, 2018). Our findings suggest that 
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efforts to expand opioid use disorder programs must include investment in programs that 
meet the specialized needs of families.  
Further, our findings offer preliminary evidence that stigma is a uniquely important 
to deterrent to treatment for adults with an opioid use disorder who live with children. 
Researchers, care providers, and the media must employ best practices when 
communicating about opioid use disorder, particularly when children and families are 
discussed (Feder & Krawczyk, 2017). While our study shows that many adults with 
opioid use disorder live with a child, communications that create the perception that 
addiction is a moral failing, that suggest children are necessarily and irreparably harmed 
by their parents’ substance use, and that obfuscate the benefit of effective treatment, may 
indirectly keep these adults from seeking the treatment they need to keep themselves and 
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Table 2.1. Characteristics of U.S. Adults with Opioid Use Disorder, 2010-2014 
  All Child In Household No Child in Household 
Population 1,987,673 815,849 1,171,824 
 Percent (95% CI) Percent (95% CI) Percent (95% CI) 
Age    
18-25 31.9 (29.3 - 34.5) 30 (26.9 - 33.1) 33.2 (29.6 - 36.8) 
26-34 30.7 (27.7 - 33.7) 35.2 (29.9 - 40.5) 27.6 (23.8 - 31.4) 
35-49 21.1 (18.2 - 24.1) 26.7 (22.2 - 31.2) 17.3 (13.7 - 20.9) 
50-64 13.9 (10.4 - 17.3) 6.3 (2.0 - 10.6) 19.1 (14.2 - 24.0) 
65+ 2.4 (0.8 - 3.9) 1.8 (0.0 - 4.4) 2.8 (0.8 - 4.8) 
Sex    
Male 60.5 (57.0 - 64.0) 54.7 (50.1 - 59.3) 64.5 (59.9 - 69.1) 
Female 39.5 (36.0 - 43.0) 45.3 (40.7 - 49.9) 35.5 (30.9 - 40.1) 
Race/Ethnicity    
White 72 (68.9 - 75.1) 69.2 (64.1 - 74.2) 74 (69.8 - 78.3) 
Black 9.9 (7.7 - 12) 9 (5.9 - 12) 10.5 (7.4 - 13.7) 
Hispanic 12.9 (10.4 - 15.4) 16 (11.9 - 20.1) 10.8 (7.8 - 13.8) 
Other 5.1 (3.8 - 6.5) 5.9 (3.7 - 8.1) 4.6 (2.9 - 6.3) 
Education Level    
Less than High School 23.8 (20.8 - 26.8) 28.3 (23.5 - 33.1) 20.6 (17.5 - 23.8) 
High School 34.6 (31.5 - 37.6) 37.3 (32.4 - 42.3) 32.6 (28.3 - 37) 
Some College 30.7 (27.5 - 34) 25.5 (22.1 - 28.8) 34.4 (29.4 - 39.4) 
College 10.9 (9.3 - 12.6) 8.9 (6.5 - 11.3) 12.3 (9.9 - 14.8) 
Employment Status    
Full Time 41.4 (37.6 - 45.1) 43.6 (38.4 - 48.8) 39.8 (35.3 - 44.3) 
Part Time 16 (13.5 - 18.6) 14.4 (11.8 - 17.0) 17.2 (13.4 - 21.0) 
Unemployed 14.8 (12.8 - 16.7) 16.8 (13.7 - 19.9) 13.4 (11.1 - 15.7) 
Other 27.8 (24.7 - 31.0) 25.2 (21.1 - 29.3) 29.7 (25.1 - 34.3) 
Urbanicity    
Large Metro 53.8 (50.8 - 56.8) 49.5 (45.4 - 53.6) 56.9 (52.9 - 60.8) 
Small Metro 31.4 (28.6 - 34.3) 31.2 (26.7 - 35.6) 31.6 (28.1 - 35.2) 
Non-Metro 14.7 (12.6 - 16.8) 19.4 (15.8 - 23.0) 11.5 (8.9 - 14.1) 
Comorbid Substance Use    
Alcohol Use Disorder 36.1 (33.2 - 38.9) 31.6 (28 - 35.3) 39.1 (35 - 43.3) 
Past-Year Cigarette Use 78.4 (75.1 - 81.7) 76.5 (71.3 - 81.6) 79.8 (75.8 - 83.7) 
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   Percent (95% CI)   Percent (95% CI)   Percent (95% CI)   OR (95% CI)   OR (95% CI)  
Any Past Year Treatment 29.6 (26.3 - 33) 27.7 (23.5 - 31.9) 31.0 (26.7 - 35.2) 0.85 (0.66 - 1.11) 0.91 (0.7 - 1.18) 
Treatment Location (% of Treated)        
Hospital 41.8 (36.4 - 47.1) 36.1 (27.2 - 45.0) 45.3 (38.1 - 52.5) 0.68 (0.41 - 1.14) 0.79 (0.45 - 1.39) 
Inpatient 47.8 (42.5 - 53) 42.8 (34.5 - 51.1) 50.9 (43.5 - 58.2) 0.72 (0.45 - 1.17) 0.75 (0.45 - 1.26) 
Outpatient 56.2 (50.8 - 61.7) 60.2 (52.3 - 68.1) 53.8 (46.4 - 61.1) 1.3 (0.83 - 2.05) 1.6 (1 - 2.57) 
Mental Health Center 34.4 (29.5 - 39.3) 34.6 (27.7 - 41.6) 34.3 (27.4 - 41.1) 1.02 (0.65 - 1.58) 1.03 (0.63 - 1.66) 
Emergency Department 28.6 (23.5 - 33.7) 25.8 (18.8 - 32.9) 30.4 (23.7 - 37.1) 0.8 (0.49 - 1.29) 1.09 (0.59 - 2) 
Physician's Office 31.5 (26.1 - 36.9) 35.3 (27.9 - 42.8) 29.2 (21.6 - 36.7) 1.33 (0.81 - 2.18) 1.46 (0.88 - 2.41) 
Jail or Prison 11.7 (8.0 - 15.5) 9.1 (4.4 - 13.9) 13.3 (7.9 - 18.8) 0.65 (0.3 - 1.42) 0.76 (0.33 - 1.77) 
Self Help Group 61.6 (57.1 - 66.2) 58.4 (51.5 - 65.4) 63.7 (57.3 - 70) 0.8 (0.53 - 1.22) 1.01 (0.61 - 1.67) 
Payment Source (% of Treated)        
Insurance 39.1 (33.3 - 44.9) 39.9 (32.2 - 47.7) 38.6 (30.9 - 46.3) 1.06 (0.68 - 1.65) 0.94 (0.58 - 1.51) 
Savings 46.3 (40.3 - 52.3) 51.5 (44.1 - 58.9) 43 (34.8 - 51.1) 1.41 (0.91 - 2.17) 1.26 (0.83 - 1.93) 
Family or Friend 33.4 (27.5 - 39.3) 33.7 (24.9 - 42.4) 33.2 (25.6 - 40.8) 1.02 (0.61 - 1.71) 1.18 (0.66 - 2.09) 
Court 7.0 (4.1 - 10.0) 5.9 (2.7 - 9.1) 7.7 (3.4 - 12.1) 0.75 (0.33 - 1.73) 0.89 (0.39 - 2.03) 
         
Perceived Need for Treatment 13.9 (11.8 - 15.9) 14.8 (10.8 - 18.9) 13.2 (10.8 - 15.6) 1.15 (0.76 - 1.72) 1.17 (0.73 - 1.88) 
Barriers (% of Persons with Perceived Need)        
Financial 55.9 (47.1 - 64.6) 60.8 (47 - 74.6) 52 (42.3 - 61.8) 1.43 (0.73 - 2.8) 0.96 (0.51 - 1.82) 
Access 25.4 (16.1 - 34.6) 34.9 (18.7 - 51.1) 17.9 (11.3 - 24.6) 2.45 (1.1 - 5.46) 2.9 (1.19 - 7.07) 
Stigma 27.1 (19.2 - 35.1) 37.3 (22.6 - 52) 19.2 (11.3 - 27.1) 2.51 (1.09 - 5.79) 4.09 (1.5 - 11.17) 
Not Ready to Stop Using 23.3 (17.7 - 29.0) 14 (6.6 - 21.3) 30.7 (22.7 - 38.7) 0.37 (0.17 - 0.8) 0.39 (0.19 - 0.8) 
Not Priority 9.7 (4.9 - 14.6) 13.3 (3.9 - 22.7) 6.9 (3.2 - 10.7) 2.06 (0.78 - 5.43) 2.79 (1.17 - 6.62) 
Note: Adjusted odds ratios adjusted for age, sex, race/ethnicity, education, employment, urbanicity, presence of an alcohol use 
disorder in the past year, and past year cigarette use. 
Note: Odds ratios statistically significant at the p<.05 level are bolded.  
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Figure 2.1. Treatment Use and Perceived Need for Treatment by Presence of Child 





CHAPTER 3. COMMON TRAJECTORIES OF HEROIN AND COCAINE USE 
OVER THE LIFE COURSE: A 30-YEAR COHORT STUDY OF PEOPLE WHO 





Background: Substance misuse disorders and overdose are a leading cause of 
morbidity and mortality among U.S. adults. Substance misuse behaviors are known to be 
chronic, but their course is not well characterized over the life span, especially among 
persons not in treatment. 
Methods: Data come from ALIVE, a longitudinal cohort under observation since 
1988 with community-based recruitment of 2,845 adults from the Baltimore area who 
currently inject or formerly injected drugs.  Past six-month heroin and cocaine use by any 
route of administration were assessed at twice-annual study visits conducted between 
1988 until 2016. Latent class linear mixed models were used to identify and describe 
common trajectories of use for each these drugs over the life course. 
 Results: Female participants attended 29% of visits, and Black participants 
attended 93%. Heroin and cocaine use were reported at 47% and 49% of visits 
respecitively. In single-class models, the predicted probabilities of past six-month use 
declined gradually from 67% and 69% at age 30 to 23% and 22% by age 60 for heroin 
and cocaine respectively. Latent class models revealed up to six common trajectories of 
use for both heroin and cocaine, with very similar class structures. In particular, for both 
drugs, sub-groups include three “cessation” trajectories that decline to zero probability of 
use; a diminishing trajectory with declining probability of use that does not reach zero by 
age 60; a relapsing trajectory with risk hovering around 50% over the entire period from 
age 30 to 60; and an “accelerating” trajectory with low risk of use in midlife but high risk 
of relapse in later life. 
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 Conclusion: The course of heroin and cocaine use over an extended period of 
adult life is heterogeneous among people who inject drugs. Future research on this 
heterogeneity can inform long-term management and differentiation of treatment for 





 The United States is currently experiencing an unprecedented epidemic of drug-
related problems. In 2017, an estimated 72,000 Americans died from a drug overdose 
(National Institute on Drug Abuse, 2018). This increase in drug-involved deaths was 
primarily caused by deaths from opioid drugs, including synthetic opioids like fentanyl, 
heroin, and prescription opioid pain-relievers. In addition, cocaine-related deaths have 
increased sharply (Seth, 2018), an increase that likely reflects increases in the use of 
cocaine mixed with fentanyl-like drugs (Miller, Stogner, Miller, & Blough, 2017). 
Opioid-related inpatient hospital admissions have increased (Healthcare Cost and 
Utilization Project (HCUP), 2018), as have cases of opioid use in pregnancy and related 
birth complications (Patrick et al., 2012).  These increases in drug-related problems were 
so dramatic that they were a primary contributor to an overall declines in life expectancy 
in the United States (Associated Press, 2018; Murphy, Xu, Kochanek, & Arias, n.d.). 
 While acute health problems like overdose deaths have received most research 
and media attention, by 2016, 2.1 million Americans were living with an opioid use 
disorder and 960,000 were living with a cocaine use disorder (Ahrnsbrak, Bose, Hedden, 
Lipari, & Park-Lee, 2017). Substance use disorders are chronic conditions characterized 
by periods of remission and relapse and frequent comorbidity with other physical and 
mental health problems (McLellan, Lewis, O’Brien, & Kleber, 2000; Saitz, Larson, 
LaBelle, Richardson, & Samet, 2008). This has motivated support for addressing 
substance use disorders through a chronic disease management approach over the life 
course, similar to diseases like diabetes (Saitz et al., 2008). Further, having a use disorder 
is a major risk factor for drug-involved death (Kolodny et al., 2015), and effective 
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addiction treatment must be a cornerstone of addressing the overdose crisis (Christie et 
al., n.d.; Kolodny et al., 2015). To meet the needs of a growing number of Americans 
living with substance use disorder, research is needed to understand the long-term 
progress of opioid use and other drug use in people with opioid use disorder over the 
course of adult life.  
Research on the course of substance use disorders, and opioid use disorder in 
particular, is limited. A number of long-term cohort studies have followed heroin users 
over a long period of time. These studies are consistent in finding that attempts to cease 
heroin use are common but most people relapse at some point; co-occurring physical and 
mental health problems are the norm, not an exception; risk for illicit use is lowest when 
participants receive medication assisted treatment, for example for with buprenorphine-
naloxone; and mortality rates in this population are very high, particularly during periods 
of active use when overdose death is the leading cause of death (Haastrup & Jepsen, 
1988; Hser, Hoffman, Grella, & Anglin, 2001; Price, Risk, & Spitznagel, 2001; Robins & 
Slobodyan, 2003; Weiss et al., 2011). Most of these studies are limited by unique 
samples, for example of people in treatment or of Vietnam War veterans.  
Further, most of the existing studies look for trajectories of behavior common to 
the whole population. Instead, there may be subtypes of users or people with use disorder 
who experience different trajectories of use over different stages of life. Identifying these 
subgroups is challenging, because, as with most behavioral disorders, there are no 
biomarkers to distinguish members of one subtype from another. Instead, two studies 
have used latent variable methods to parse out latent subgroups of heroin users. First, 
Hser and colleagues followed a sample of 471 male heroin users from a California 
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treatment program for fifteen years following first use. They identified three types of 
users – a group of early quitters, a group of stable high users, and a group of 
“decelerated” users whose use declined after a decade, but never ceased (Hser, Huang, 
Chou, & Anglin, 2007). Second, Genberg and colleagues (Genberg et al., 2011) followed 
a cohort of 1,700 people living in Baltimore recruited into a longitudinal cohort study of 
people who injected drugs (mostly heroin users) over a 20-year period from their time of 
entry into the study. They identified five common trajectories of injection drug use – 
early, delayed, and late cessation groups, a relapsing group, and a group of sustained 
users who made up about a third of the sample. 
This study builds on the work of Genberg and colleagues. We use ten additional 
years of data from the same active cohort study, and focused on participant age, rather 
than time since entry. We also explore distinct trajectories of use of two specific drugs – 
heroin and cocaine – rather than injecting behavior generally. With thirty years of data 
combined from six recruitment periods, we can characterize the trajectories of use for 
these drugs over an extended period of the adult life in a community-based sample and 
explore differences in the course of heroin and cocaine use. 
3.2 Materials and Methods 
3.2.1 Study Participants 
  Study participants come from the AIDS Linked to the Intravenous Experience 
(ALIVE) study, an active, community-based, prospective cohort study of adults living in 
and around Baltimore City, Maryland. In 1988, 2,946 participants who had injected drugs 
in the prior 10 years were recruited to study the natural history of HIV (Vlahov et al., 
1991). Additional waves of recruitment were conducted in 1994-1995 1998, 2000, 2005-
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2008, and 2015-2018 to replenish the original sample; later recruitment waves required 
participants to have injected drugs at least once in the past year (as opposed to in the past 
10 years as for the original recruitment). Participants attend twice annual study visits 
where they complete a physical exam,  standardized interviewer-administered and audio-
computer assisted surveys about drug use and related behaviors, and provide a blood 
sample for HIV testing. Once enrolled, participants remain in the ALIVE cohort until 
they die, choose to exit the study, or are lost to follow up.  The Johns Hopkins University 
Institutional Review Board approved the study and all participants provided informed 
written consent. Details of ALIVE are described elsewhere (Vlahov et al., 1991).  
 The present analysis used data from all ALIVE participants who attended at least 
four study visits between in May of 1988 and December of 2016. Of the original sample 
of 60,137 study visits, 1,541 visits were excluded because data on either heroin or 
cocaine use were missing, and another 2,114 because participants had been in follow-up 
for fewer than four total visits at the time of analysis. This left a final sample of 2,845 
participants who contributed 56,482 study visits. The median number of visits 
contributed by a participant was 16 (IQR 9 visits to 28 vsitis). This sample was used in 
the main analysis of both heroin and cocaine outcomes. 
The median time between study visits was 183 days (IQR 179 days to 202 days). 
Participants are eligible to remain in ALIVE until death, and may go extended periods 
without attending study visits. In this sample, the longest period between two study visits 
was under 415 days for 50% of the sample and 1,427 days for 90% of the sample; the 
longest gap between study visits in our sample was 25 years (see  Limitations for further 
discussion of missing data). 
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3.2.2 Measures 
Two outcomes were assessed in this analysis: 1) Past six-month heroin use by any 
route of administration assessed in ALIVE (including injecting heroin alone, snorting 
heroin alone, smoking heroin alone, and injecting heroin and cocaine simultaneously); 
and 2) Past six-month cocaine use by any route of administration assessed in ALIVE 
(including injecting cocaine alone, snorting cocaine, smoking crack cocaine, and 
injecting heroin and cocaine simultaneously). All outcomes were assessed via self-report 
in response to audio-computer-assisted-survey instruments (ACASI).  
The primary independent variable was age in days. We adjusted for a small 
number of other covariates – demographic variables including sex (male, female) and 
race (black, white); and study-specific variables including decade of study visit (1980s, 
1990s, 2000s, 2010s) and recruitment cohort (initial 1988 recruitment, or all other 
cohorts). This limited set of time-invariant covariates was selected because the goal of the 
study was to describe the natural history of drug use over the life course by estimating the 
probability of use as a function of age. Adjusting for other, time-varying covariates 
would be adjusting for mediators, and would bias the estimated association of age with 
drug use.  
Finally, mortality and date of death for each participant was obtained from the 
National Death Index (NDI) with confirmation from death certificates. 
3.3.3 Analytic Approach 
 The analysis was conducted separately for each of the two outcomes, but the 
approach was the same for both outcomes. Therefore, the “Approach” section refers 
generally to the outcome variable as “drug use.” 
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 3.2.3.1 Single Class Model. We first estimated the conditional probability of drug 
use as a function of age using generalized linear models with a probit link. We included 
linear and quadratic age terms, to allow for non-linear trends over time. Models adjusted 
for sex, race, study visit decade, and recruitment cohort. Random intercepts were used to 
account for the fact that repeated observations on the same participant are correlated. The 
mean estimated conditional probability of drug use was estimated and plotted as a 
function of age for ages 30 through 60 (approximately 95% of study visits fell in this 
range); for a hypothetical male Black participant (the most common demographic); 
recruited in cohorts other than the initial 1988 recruitment (i.e. more recent recruitments); 
attending a study visit in the 2010s (to make inference more relevant to the present day); 
and with a random intercept of 0.  
 3.2.3.2 Multiple Class Models. The goal of the main analysis was to identify 
subgroups of users who share a similar pattern of drug use over the life course.  To do 
this, we used latent class linear mixed models (also known as growth mixture models). 
These models extend the regression conducted in the preliminary analysis to 
accommodate the possibility of two or more sub-populations (or “latent classes”) of drug 
users, each with its own set of model parameters (Proust-Lima, Philipps, & Liquet, 2015). 
Specifically, the latent class linear mixed model assumes that each study participant is a 
member of exactly one of a finite number of classes, but this class status is unknown. The 
proportion of the population in each class, and the set of parameters associated with each 
class, are estimated simultaneously. In this analysis, only coefficients for the linear and 
quadratic age terms were allowed to differ across classes. All other parameters – all other 
regression coefficients, the regression intercept, and the random intercept variance – were 
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constrained to be the same for every class. Forcing the regression intercept to be the same 
across classes was used to impose the constraint that the conditional probability of use at 
age 20 was the same for all classes. This assumption reflects the fact that all participants 
were recruited based on their history of drug use, and prevents estimation of unrealistic 
classes with a very low probability of drug use at the beginning of adulthood. 
 We estimated models with 2, 3, 4, 5, and 6 classes. The model that best fit the 
data – as indicated by Akaike Information Criteria (AIC) and Bayesian Information 
Criteria (BIC) – was chosen for presentation and analysis.  For that best-fitting model, as 
with the one-class models, the mean estimated conditional probability of drug use in each 
class was plotted as a function of age for ages 30 through 60, for a hypothetical male 
Black participant; recruited in waves other than the initial 1988 recruitment; attending a 
study visit in the 2010s; and with a random intercept of 0. We also name each class to 
qualitatively describe its trajectory, and present the proportion of the sample estimated to 
belong to each class.  
3.2.3.3. Sensitivity Analyses -- Participants Surviving to 2016. Mortality rates 
in the ALIVE cohort are high – 49% of study participants contributing 40% of all study 
visits were deceased by the end of the observation period. This means that modeled 
trajectories of drug use at older ages increasingly reflect only the behavior of participants 
who will have survived to that point. For this reason, the entire analysis was repeated on a 
sample of participants still living at the end of the observation period (33,229 
observations of 1,421 participants), to see if common trajectories of use are similar in 
drug users who survive. 
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3.2.3.4 Inference. All predicted probabilities are presented with 95% Wald 
confidence intervals. Statistical significane of regression coefficients is assessed at the 
p<.05 level with t-tests. 
 3.2.3.5 Software. All analyses were conducted in R 3.5.0 using the “lcmm” 
package (Proust-Lima et al., 2015). The lcmm package uses a Marquardt algorithm – a 
Newton-Raphson-like algorithm – to find maximum likelihood estimates and standard 
errors for all parameters. For multi-class models, multiple sets of random starting values 
were used to decrease the chance of models converging to a local, rather than global, 
maximum likelihood. 
3.3 Results 
3.3.1 Sample Characteristics 
 Past-six-month heroin use was reported at 47 percent of study visits, and past six-
month cocaine use at 49 percent of study visits. The median age was 44.7 years. Half of 
all study visits came from participants between ages 38 and 51, and 90% came from 
participants between the ages of 30 and 60.  The minimum age at any study visit was 19 
years, and the maximum 81 years. Seventy-one percent of study visits had a male 
participant, and 93% had a Black participant. Approximately 33% of visits came from 
participants who were recruited at some time other than the initial recruitment conducted 
in 1988. Approximately 5% of visits were attened in the 1980s, 44% in the 1990s, 31% in 
the 2000s, and 20% in the 2010s. 
3.3.2 Single-Class Model 
 In general, the predicted probability of both heroin and cocaine use declined 
steadily with age. 
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 3.3.2.1 Heroin. The conditional predicted probability of past six-month heroin 
use at age 30 – for a male, Black participant, from the later recruitment waves, attending 
a study visit in the 2010s, with a random intercept of zero – was 66.5%. This declined to 
53.3% by age 40, 38.2% by age 50, and 23.4% by age 60 (Figure 1). 
 3.3.2.2 Cocaine. The conditional predicted probability of past six-month heroin 
use at age 30 – for a male, Black participant, from the later recruitment waves, attending 
a study visit in the 2010s, with a random intercept of zero – was 68.6%. This declined to 
54.5% by age 40, 38.0% by age 50, and 22.3% by age 60 (Figure 1). 
3.3.3 Model Selection 
 Table 2 shows log-likelihood, AIC, and BIC statistics for two- through six-class 
models, for both heroin and cocaine use. For both outcomes, six-class models had the 
lowest AIC and BIC, suggesting these models best fit the data, and that the simple 
trajectory described above may actually average over as many as six different common 
latent subtypes of people who use heroin and cocaine respectively who experience 
different trajectories of use over the life course.  
3.3.4 Best-Fitting Model 
3.3.4.1 Heroin. Figure 1 shows the declining risk of heroin use over the life 
course disaggregated into six latent trajectories. There are three “cessation” trajectories, 
characterized by a high probability of use at age 30 eventually reaching zero probability 
of use by a user’s late 30s (10%), mid-40s (11%), or mid-50s (24%). A fourth group of 
“diminishing” users (24%) also experienced consistent declining average probability of 
use over the life course, but that probability did not reach zero by age 60. A fifth group of 
“relapsing” users experienced relatively steady moderate probability of use (22%). 
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Finally, the sixth group of users (10%) had an “accelerating” probability of use that 
increased over the life course. 
3.3.4.2 Cocaine. Figure 2 shows the declining risk of cocaine use over the life 
course disaggregated into six latent trajectories. There are three “cessation” trajectories, 
characterized by eventually reaching zero probability of use by a user’s early early-30s 
(5%), early-40s (13%), and early-50s (18%). A fourth group of “diminishing” users 
(29%) also experienced consistent declining average probability of use over the life 
course, but that probability did not quite reach zero by age 60. A fifth group of 
“relapsing” users experienced relatively steady moderate probability of use (27%). 
Finally, the sixth group of users (9%) had had an “accelerating” probability of use that 
increased over the life course. 
3.3.5 Other Covariates 
 The predicted trajectories shown are for a male, Black participant, recruited after 
the initial 1988 recruitment, attending a study visit in the 2010s (Table 1). Probit 
regression coefficients from the best-fitting six class model show race, gender, 
recruitment cohort, and visit era were all significantly associated with both heroin and 
cocaine use.  
3.3.5.1 Heroin. All other characteristics held equal, female participants had 
significantly lower probability of heroin use than male participants (B = -0.31, p = 
<.001), Black participants had significantly higher probability of heroin use than White 
participants (B = 0.35, p=.002), participants recruited after 1988 had significantly higher 
probability of heroin use than participants recruited in 1988 (B = 0.84, p <.001), and 
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study visits in the 1990s (B = -.23, p <.001), 2000s (B = -.71, p<.001), and 2010s (B – 
1.27, p<.001) had successively lower rates of heroin use than visits in the 1980s. 
3.3.5.2 Cocaine. All other characteristics held equal, female participants had 
significantly lower probability of cocaine use than male participants (B = -0.16, p = 
.003), Black participants had significantly higher probability of cocaine use than White 
participants (B = 0.47, p<.001), participants recruited after 1988 had significantly higher 
probability of cocaine use than participants recruited in 1988 (B = 0.58, p <.001), and 
study visits in the 1990s (B = -.56, p <.001), 2000s (B = -1.12, p<.001), and 2010s (B = -
1.58, p<.001) had successively lower rates of cocaine use than visits in the 1980s. 
3.3.6 Sensitivity Analyses -- Participants Surviving to 2016 
Results of the analysis repeated on the subsample of participants who survived until 
2016 are shown in the Appendix Exhibits. As in the full sample, six-class models had the 
lowest AIC and BIC for both heroin and cocaine. Class structures were similar, but in 
general cessation classes tended to approach zero probability of use at younger ages.  
3.4. Discussion 
The analysis presented here offers new insight into the diverse possible courses of 
heroin and cocaine across the adult life of people with a history of injection drug use. 
While on average, the probability of continuing to use both drugs declines with age, this 
analysis suggests that this population-average decline may mask as many as six subtypes 
of users who experience a different course of disorder over the life course. Further, we 
find that these subtypes were actually quite similar for heroin and cocaine use. We did 
not model heroin and cocaine use in a joint model, mostly because of statistical 
constraints – due to the very long time period of observation with most cohort members 
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observed for only part of the study period and because of the large number of classes 
explored, it was difficult to achieve convergence of the optimization algorithm used in 
model fitting. However, the similarity in class structure suggests that the trajectories 
observed are more a portrait of substance misuse behavior generally in people who inject 
drugs, rather than distinct trajectories of heroin and cocaine use respectively. 
Specifically, for each drug: 1) We found three “cessation” groups – comprising 
around two-fifths of the sample for both heroin and cocaine use – that declined from 
higher than 50% probability of use to zero probability of use by participants mid 30s, 40s, 
or 50s, depending on group membership. 1) We found a “relapsing” group – comprised 
of a quarter of the cohort whether heroin or cocaine is the drug use outcome – who had a 
probability of use of just under 50% at every visit from age 30 to 60. 3) We found a 
“diminishing” group – collectively comprising about a quarter of the sample for both 
heroin and cocaine use – that also experienced declining probability of use with age, but 
that probability did not reach 0 by age 60. 4) Finally, about a tenth of the cohort for 
heroin use, and slightly less than that for cocaine use, experienced an accelerating pattern 
of use. These cohort members had achieved a low probability of use in mid-life, but this 
increased dramatically with age – in other words, this group experienced very high 
probability of relapse even after a long period of minimal use in midlife.  
Taken together, aside from painting a novel portrait of the diverse courses that heroin 
and cocaine use can take over adult life, the subgroups described lend themselves to at 
least two practical conclusions. First, the course of heroin and cocaine use over adult life 
is more complex than previously described. Recall that Hser and colleagues (Hser et al., 
2007) identified three latent trajectories of heroin use in a sample of about 500 
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participants, and Genberg and colleagues (Genberg et al., 2011) identified five latent 
trajectories of injection drug use in this same cohort, but with fewer study visits. We 
identified six latent trajectories, but did not test for seven or more class models, primarily 
because of sample size and interpretability constraints. It is reasonable to think that, if an 
even larger sample were available, more latent classes might be identified. In some 
respects, this is a limitation of the analysis – it strongly suggests that there are not “truly” 
some finite number of subgroups of people who use heroin or cocaine that could 
theoretically be identified with biological or behavior markers (or better modeling 
techniques). However, identifying more classes serves to illustrate the complexity of 
substance use disorders, and highlight less common, but still fairly prevalent, common 
trajectories of use. 
Second, less than half of the sample – for both cocaine and heroin outcomes – fell in 
a cessation trajectory that achieved zero probability of use by age 60. The remainder had 
a non-trivial probability of heroin use even after age sixty. In fact, just under a tenth of 
the sample experienced accelerating trajectories with increasing risk for (heroin or 
cocaine) use late in life. This underscores the chronic nature of drug use behavior for 
these drugs, and also suggests that there is a not insignificant group who – even after an 
extended period with low to moderate drug use – will relapse to frequent in late life. 
Recognizing this underlying heterogeneity that characterizes the course of heroin, 
cocaine, and speedball has implications for the present opioid epidemic. In particular, the 
findings presented here suggest that, though the current spike in overdose deaths is often 
treated as a short-term disaster or “crisis,” in reality millions of Americans are struggling 
with chronic disorders, and many of these likely will continue to use opioid drugs like 
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heroin or co-use stimulants like cocaine for much of their adult lives; others who cease 
use may start again many years later. Efforts to identify these subgroups of high-risk 
users, and meeting the needs resulting from the impairment that likely accompanies this 
chronic use, will be an important complementary effort to emergency services to reduce 
overdose death rates. 
Finally, we should note that we repeated our analysis among the sample of study 
participants who were still living in 2016. Surprisingly, while there were some 
differences, we found a generally similar class structure and similar class prevalences. In 
fact, it is worth noting that, even in this group of survivors, 11% of the sample 
demonstrated an “accelerating” trajectory for heroin use and 7% demonstrated an 
“accelerating” trajectory for cocaine use. More research is needed to understand the 
characteristics of this sub-population of adults who survive into older adulthood even as 
they relapse into very high probability of drug use. 
The present analysis is descriptive, and is designed to motivate future research. The 
three conclusions noted, and their implications for the present opioid epidemic, strongly 
lend themselves to four follow-up areas of research: 
1. What are the early-life characteristics that predict membership in one or another 
latent drug-use class for heroin or cocaine? 
2. What are the factors that, over the course of life, modify the course of drug use, 
and do these factors vary by latent class membership? In other words, do 
different “types” of heroin and cocaine users have different sets of risk factors for 
persistent use or relapse? 
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3. How do heroin and cocaine use interact? How does use of one drug affect the 
onset or cessation of the other? 
4. How is class membership, and the course of heroin or cocaine use more 
generally, associated with mortality? 
These are all questions that can, and should, be answered through further analysis of the 
ALIVE cohort. 
This study has a number of limitations. First, the cohort is comprised of Baltimore-
area adults recruited in waves throughout the 1980s, 1990s, and 2000s. The strengths of 
this cohort for understanding long-term trajectories of drug use are that ALIVE is not a 
sample of people in treatment, and ALIVE has a very long period of follow-up. However, 
this mostly male, mostly African American, almost exclusively urban, east-coast cohort – 
many of whom came of age during the peak of the HIV epidemic – are very different 
from the general population of drug users. In particular, there is an urgent need for 
research on rural substance use – trajectories of use may be very different in rural 
communities, where treatment availability is scarce (Jones, Campopiano, Baldwin, & 
McCance-Katz, 2015). Second, ALIVE participants are also unique in that they were 
recruited because they have a history of injecting drugs. Injection drug use may be a 
marker for severity of drug-related problems; different trajectories might be observed in 
the broader cohort of adults who use heroin or cocaine but have never injected. Third, 
latent variable methods can be unstable, and class structure and size estimates may differ 
when estimated in different populations. This limitation is particularly noteworthy in this 
study because of the first limitation – the geographic specificity of the ALIVE cohort. 
Fourth, the trajectories in this study relied on parametric assumptions, most importantly 
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1) a quadratic time trend and 2) a common probability of use across all classes at age 20. 
In the strictest sense, these assumptions are probably not accurate, and the former in 
particular is a limitation since participants were recruited at different ages, so it is 
difficult to know what their probability of drug use at 20 would have been. However, 
while more flexible model specifications are possible, they may come at the price of 
interpretability or, more practically, may simply not be estimable without a very large 
sample. The appropriate way to interpret the classes presented in this study are as an 
illustration of general trends, not as exact estimates of the probability of use at any 
particular age. Fifth, latent class linear mixed models assume each study participant is a 
member of exactly one, discrete class. In the strictest sense, this assumption is also not 
realistic in this study – it is implausible that there is a single biomarker like a gene that 
dictates the course of substance use disorder over the life course. Further, as a practical 
matter, the trajectories identified sometimes overlap in probability space, and their 
entropies are low (Table 2) (Celeux & Soromenho, 1996), suggesting poor class 
differentiation. It is more appropriate to view this analysis as a tool for identifying 
common trajectories of drug use, rather than of identifying truly distinct classes of users. 
Sixth, random intercept models are unbiased so long as study visits are “missing at 
random” (Bell, Kenward, Fairclough, & Horton, 2013), where “missing at random” refers 
to the concept defined by Rubin (Rubin, 1976). However, in addition to survival bias 
(addressed in our sensitivity analysis), study visits may be missing “not at random” if, 
during periods when participants did not attend visits, they were systematically more (or 
less) likely to be using heroin or cocaine. If this is the case, then estimated trajectories 
would be biased.   
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 This study is the first to examine the heterogeneity of heroin, cocaine, and 
speedball use in a community population sample over an extended period of adult life. 
Findings suggest that the average declines in the probability of use over the course of life 
may mask distinct groups of high and low risk users. Future research is needed to better 
identify these groups, understand their needs, and reduce the proportion of drug users 
who continue to use throughout the course of adulthood.   
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Table 3.1. Prevalence of Drug Use, Characteristics, by Age Quartile at Visit 
  All Q1: 19-38 Q2: 38-44 Q3: 44-51 Q4: 51-81 
Number of Study Visits 56482 14128 14113 14129 14112 
Heroin 46.6% 60.8% 54.5% 42.6% 28.4% 
Cocaine 48.7% 63.6% 56.8% 44.3% 30.0% 
Female 28.8% 32.1% 30.1% 28.7% 24.1% 
Black 93.4% 91.1% 93.6% 94.1% 95.0% 
Recruited After 1988 33.0% 23.8% 29.5% 37.7% 40.9% 
1980s 5.3% 14.5% 4.8% 1.5% 0.3% 
1990s 43.7% 69.8% 60.0% 34.7% 10.5% 
2000s 30.6% 12.1% 28.3% 44.5% 37.4% 




Table 3.2. Fit Statistics for Latent Class Models with 2-6 Classes 
Number of Classes 2 Class 3 Class 4 Class 5 Class 6 Class 
Heroin      
Log Likelihood -25507.697 -25128.335 -24946.058 -24863.072 -24743.543 
Entropy 0.41427156 0.51407239 0.42997516 0.42986008 0.44837635 
AIC 51041.3948 50288.6695 49930.1167 49770.1433 49537.0863 
BIC 51118.7879 50383.9226 50043.2298 49901.1163 49685.9192 
Cocaine      
Log Likelihood -24966.063 -24547.4 -24372.853 -24247.39 -24167.732 
Entropy 0.40965059 0.45805936 0.43864151 0.46214933 0.50176624 
AIC 49958.1268 49126.8001 48783.7057 48538.7802 48385.4641 




Figure 3.1. Single-Class (Pooled) and Six-Class Estimates of Predicted Probability of 
Heroin Use at Ages 30-60 in Baltimore Adults who Injected Drugs 
 
Note: Predictions for hypothetical male, Black participant, recruited in a post-1988 wave, 
attending a study visit in the 2010s, and with a random intercept of 0.  
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Figure 3.2. Single-Class (Pooled) and Six-Class Estimates of Predicted Probability of 
Cocaine Use at Ages 30-60 in Baltimore Adults who Injected Drugs 
 
Note: Predictions for hypothetical male, Black participant, recruited in a post-1988 wave, 
attending a study visit in the 2010s, and with a random intercept of 0.  
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3.8 Appendix Exhibits 
 
Table 3.1a. Prevalence of Drug Use, Characteristics, by Age Quartile at Visit, 
among Persons who Survived to 2016 
  All Q1: 19-38 Q2: 38-44 Q3: 44-51 Q4: 51-81 
Number of Study 
Visits 33229 8309 8308 8307 8305 
Heroin 41.7% 60.1% 48.8% 34.7% 23.4% 
Cocaine 43.4% 59.5% 49.9% 37.4% 26.7% 
Female 30.8% 32.7% 33.5% 32.1% 24.8% 
Black 92.8% 87.9% 93.0% 94.3% 96.0% 
Recruited After 1988 43.4% 35.3% 43.2% 48.8% 46.3% 
1980s 2.9% 9.6% 1.8% 0.3% 0.0% 
1990s 32.1% 65.8% 44.4% 15.1% 2.9% 
2000s 34.3% 18.4% 40.7% 49.3% 28.6% 
2010s 30.7% 6.2% 13.1% 35.2% 68.5% 
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Table 3.2a. Fit Statistics for Latent Class Models with 2-6 Classes, among Persons 
who Survived to 2016 
Number of Classes 2 Class 3 Class 4 Class 5 Class 6 Class 
Heroin      
Log Likelihood -14445.728 -14203.925 -14104.999 -14052.541 -13981.746 
Entropy 0.48787741 0.50945642 0.47376305 0.46683488 0.49730096 
AIC 28917.4555 28439.8501 28247.9973 28149.0815 28013.4918 
BIC 28985.824 28523.996 28347.9205 28264.7821 28144.9697 
Cocaine      
Log Likelihood -14174.157 -13918.845 -13819.911 -13763.713 -13693.341 
Entropy 0.51046892 0.52114598 0.48249954 0.47990204 0.52871646 
AIC 28374.3142 27869.6891 27677.8214 27571.4252 27436.6823 




Figure 3.1a. Single-Class (Pooled) and Six-Class Estimates of Predicted Probability 
of Heroin Use at Ages 30-60 in Baltimore Adults who Injected Drugs and Survived 
to 2017 
 
Note: Predictions for hypothetical male, Black participant, recruited in a post-1988 wave, 
attending a study visit in the 2010s, and with a random intercept of 0.  
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Figure 3.2a. Single-Class (Pooled) and Six-Class Estimates of Predicted Probability 
of Cocaine Use at Ages 30-60 in Baltimore Adults who Injected Drugs and Survived 
to 2017 
 
Note: Predictions for hypothetical male, Black participant, recruited in a post-1988 wave, 
attending a study visit in the 2010s, and with a random intercept of 0. 
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CHAPTER 4. ASSOCIATION OF CHILDHOOD ADVERSITY WITH HEROIN 






Background: Childhood adversity is associated with the development of 
substance use problems in adulthood, including opioid and cocaine misuse. To my 
knowledge, no research has examined how a history of childhood adversity modifies the 
course of substance use over an extended period of adult life. 
Methods: Data were collected as part of ALIVE, a longitudinal cohort under 
observation since 1988 with community-based recruitment of adults who currently inject 
or formerly injected drugs from the Baltimore area.  Past six-month heroin and cocaine 
use by any route of administration were assessed at twice-annual study visits conducted 
between 1988 and 2016. In 2018, childhood adversity was retrospectively assessed in 352 
participants via self-report interview by a trained clinician. Bayesian multilevel models 
were used to test the hypothesis that childhood adversity modifies the association of age 
with substance use. 
Results: For participants with fewer than two adverse childhood experiences, the 
probability of both heroin and cocaine use declined sharply with age, to less than 10 
percent for both heroin and cocaine by age 65. By contrast, risk for heroin and cocaine 
use persisted into older ages among participants with 5 or more adverse childhood 
experiences, remaining above 40% for both heroin and cocaine use. 
 Conclusion: Among people who have injected drugs, a history of childhood 
adversity is associated with a substantially increased probability of continuing to use 
heroin and cocaine at older ages. More research is needed to understand why the negative 




As discussed in the previous chapters, the United States is experiencing an 
unprecedented epidemic of drug-related problems. Most research on the causes of the 
United States’ ongoing epidemic has focused on proximal events that have increased 
deaths from opioids, most notably: 1) over-prescribing of opioid pain-relievers like 
OxyContin over the past three decades (Kolodny et al., 2015); 2) growing use of highly 
potent and lethal fentanyl (Miller, Stogner, Miller, & Blough, 2017; National Institute on 
Drug Abuse, 2018); and 3) increasing deaths from stimulant drugs like cocaine, often 
when used in conjunction with opioids (Miller et al., 2017; Seth, 2018).  
By contrast, the role of early-life risk factors that may influence the initiation and 
course of harmful opioid use has received comparatively little focus in the present 
epidemic. The omission of early-life risks from research and policy efforts likely reflects 
a desire to study proximal targets that may be useful for preventing overdose deaths and 
ameliorating the present crisis. However, there are reasons to believe a better 
understanding of the role of childhood risk factors in the present crisis – in particular, 
chronic childhood adversity and trauma – can play an important role in better addressing 
that crisis. This is because of the strong evidence that exposure to childhood adversity 
such as abuse, household dysfunction, or community violence are important precursors to 
opioid use disorder. 
As discussed in greater detail in the Introductory Chapter, there is strong evidence 
that exposure to abuse, household dysfunction, or other forms of adversity in childhood 
are associated with observable structural and functional changes in adult brain regions 
and systems linked to addiction (Enoch, 2011). Further, this adversity is associated with 
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increased risk for use of “street drugs,” earlier initiation of drug use, self-identified 
addiction to drugs (Dube et al., 2003), injection drug use (Ompad et al., 2005) and 
alcohol use disorder (Anda et al., 2006). In fact, childhood adversity is also related to a 
host of mental, behavioral, and physical problems linked to substance use, including 
many of the leading causes of death (Anda et al., 2006; Felitti et al., 1998). Childhood 
trauma has even been identified as a risk factor for an opioid use disorder specifically 
(Naqavi, Mohammadi, Salari, & Nakhaee, 2011), and some authors have argued that a 
history of childhood trauma plays a central role in the etiology of heroin use disorder 
(Darke, 2013). Childhood abuse and household dysfunction are also associated with 
increased risk for two of the primary drivers of the present opioid epidemic – chronic 
pain (Davis, Luecken, & Zautra, 2005) and use of a greater number of prescription 
medications (Anda, Brown, Felitti, Dube, & Giles, 2008).  
 In summary, there is a clear and strong link between childhood adversity and both 
adult substance use generally and opioid-related problems specifically. However, 
knowing that adversity increases risk for developing opioid-related problems is, while 
useful, insufficient for meeting the needs of the more than 2 million Americans who are 
already living with opioid use disorder (Ahrnsbrak, Bose, Hedden, Lipari, & Park-Lee, 
2017). To maximize prevention and intervention efforts, it is also vital to understand how 
childhood adversity affects the course of problem opioid use over the adult life span. If 
childhood adversity is differentially associated with greater probability or severity of 
drug related problems at different points in the life course, then this information can 
inform the development of interventions that explicitly address the known biological and 
psychosocial consequences of past adversity. By contrast, if childhood adversity is a risk 
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factor for the onset of drug problems, but does not influence the course of these 
problems, then trauma-oriented research and interventions designed to address trauma 
sequelae may have less utility for addressing the current opioid crisis, even if they help 
clients in other ways (e.g., by managing negative symptoms associated with trauma). 
 This study examines the effect of exposure to childhood adversity on the course 
of heroin and cocaine use over an extended period of adulthood. It uses data from the 
same AIDS Linked to the Intravenous Experience (ALIVE) study described in Chapter 3. 
In Chapter 3, we showed that average gradual declines in heroin and cocaine use with age 
may mask substantial heterogeneity in the population, with some participants relapsing to 
very high probability of use in late adulthood even after a period of extended abstinence. 
In this chapter, we examine if childhood adversity modifies the trajectory of heroin and 
cocaine use over the life course, thereby explaining some of this heterogeneity. We 
hypothesize that childhood adversity is associated with higher probability of heroin and 
cocaine use in early adulthood, but that these effects will dissipate as participants age and 
childhood experiences become more distant. 
4.2 Materials and Methods 
4.2.1 Study Participants 
  Study participants were recruited into the ALIVE study, an active, community-
based, prospective cohort study of adults living in and around Baltimore City, Maryland 
who have injected drugs and who agree to attend twice annual study visits. Details of that 
study are described in Chapter 3.   
The present analysis used data from 362 ALIVE participants who completed a 
retrospective assessment of adverse childhood experiences between August 1st and 
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December 26th of 2018. Of these, 10 participants were excluded because they declined to 
complete the section of the assessment examining child abuse (see below), for a final 
sample of 352 participants. These 352 participants collectively attended 8,231study visits 
at various points between 1988 and 2017. Of these visits, 218 were excluded because data 
on participants past six-month heroin or cocaine use were missing (see 2.2. Measures), 
leaving a final sample of 8,013 visits used in this analysis. 
(More than 362 ALIVE participants attended study visits during that time period, 
but did not complete the adverse childhood experiences assessment, primarily because of 
constraints on staff time. We did not track these participants, because data collection is 
ongoing, and we intend to offer them the opportunity to complete the questionnaire at 
their next visit.) 
The Johns Hopkins University institutional review board approved the ALIVE 
study, and data collection for this sub-study. All participants provided informed written 
consent to participate. In addition, six questions included in our assessment asked 
participants about childhood experiences that likely constitute child abuse. Maryland 
State law requires that incidents of child abuse uncovered in the context of research be 
reported by the researchers to the city Department of Social services. For this reason, 
prior to asking participants’ these six questions, participants were told:  
“In the next section, I’m going to ask some more questions about some things that 
an adult might have said or done to you before your 18th birthday. Some of these 
things could indicate that, when you were a child, you experienced abuse. For this 
reason, if you answer yes to any of these next six questions, under Maryland State 
law, I will be obligated to make a report including your name and contact 
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information to the Baltimore City Department of Social Services…. Would you 
like me to proceed with this section?” 
 If participants chose to proceed, and endorsed any of the subsequent items, a 
report was made to the Baltimore Department of Social Services, as required by 
Maryland law. Only 10 of 362 participants (3%) declined to complete this section after 
hearing this statement (see above). 
4.2.2 Measures 
4.2.2.1 Outcome. Two outcomes were assessed in this analysis: 1) Past six-month 
heroin use by any route of administration assessed in ALIVE (injecting heroin alone, 
snorting heroin alone, smoking heroin alone, and injecting heroin and cocaine 
simultaneously). 2) Past six-month cocaine use by any route of administration assessed in 
ALIVE (injecting cocaine alone, snorting cocaine, smoking crack cocaine, and injecting 
heroin and cocaine simultaneously). All outcomes were assessed at each study visit via 
self-report in response to audio-computer-assisted-survey instruments (ACASI).  
4.2.2.2 Exposure. The primary independent variable was a participant’s age in 
days at a study visit.  
4.2.2.3 Effect Modifier. Participants’ childhood exposure to adversity and trauma 
was assessed using a modified version of the Adverse Childhood Experiences 
questionnaire (Finkelhor, Shattuck, Turner, & Hamby, 2015). This assessment is based 
on the classic assessment administered by Felitti and colleagues to members of the Kaiser 
health system for the CDC’s Adverse Childhood Experience Study (Felitti et al., 1998), 
but adds four other common adverse experiences shown to predict poor outcomes 
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(Finkelhor et al., 2015). Assessments were administered as part of an in-person interview 
by trained clinicians (a nurse and nurse-practitioner).  
Fourteen adverse childhood experiences were assessed, with 21 questions: 
physical neglect (2 questions), emotional neglect (2 questions), physical abuse (2 
questions), emotional abuse (2 questions), sexual abuse (2 questions), loss of a parent to 
divorce, abandonment or “some other reason” (1 question), growing up with domestic 
violence in the home (3 questions), having a parent with an alcohol or drug use problem 
(1 question), having a parent with mental illness (1 question), having a member of the 
household go to prison (1 question), being bullied by peers (1 question), being ostracized 
by peers (1 question), growing up in a violent neighborhood (1 question), and growing up 
in poverty (1 question). For adversities assessed with multiple items, endorsing any one 
of those items was sufficient to indicate the presence of that adversity. The 14 
dichotomized items were summed to compute a scale score ranging from 0 to 14. This 
scale was further grouped into tertiles of 0-1 adversities, 2-4 adversities, and 5 or more 
adversities for analytic purposes. Tertiles were used instead of the commonly used 
grouping of 0, 1, 2, 3, or 4 or more adversities for two reasons: first, a smaller number of 
groups was needed to make age-by-adversity interaction terms estimable (see 2.3 
Analytic Approach); second, because exploratory analysis showed very high levels of 
adversity were reported in the cohort, we wanted childhood adversity groupings that 
appropriately reflect the distribution of adversity in this sample. 
4.2.2.4 Potential Confounders. We adjusted for the demographic variables 
gender (male, female) and race (Black, White) and for study-specific variables ‘decade of 
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study visit’ (1980s, 1990s, 2000s, 2010s) and ‘recruitment cohort’ (initial 1988 
recruitment, or all other cohorts).  
4.2.3 Analytic Approach 
 4.2.3.1 Summary. The analytic approach is the same for both outcome drugs 
(heroin and cocaine), so going forward we refer generally to the outcome as “drug use.” 
The goal of the analysis was to determine how a history of childhood adversity modifies 
the probability of drug use over the adult life course. We examined this question by using 
Bayesian multi-level logistic regression models to estimate the conditional probability of 
drug use as a function of age. We included an interaction term to determine whether a 
history of childhood adversity modified the association of age with drug use. We then 
estimated the relative odds of drug use comparing participants who experienced high 
levels of adversity to participants who experienced low levels of adversity, in years of life 
between age 30 and 65 (95% of study visits fell in this age range).  
 4.2.3.2 Missing Questionnaire Responses. All 352 participants whose data 
informed analyses answered at least one item on the childhood adversity assessment; 
however, 44 (12.5%) left at least one of these items unanswered. Exploratory analysis 
showed the 44 participants who failed to respond to at least one adversity question were 
more likely to endorse other adversities. To maximize our sample size and avoid inducing 
selection bias, before conducting the analysis, we multiply-imputed missing responses 
using participants’ responses to other questionnaire items with conditional mean 
matching. Five imputed datasets were created. Participants’ childhood adversity score 
was computed in each of the five imputed datasets (see 2.2.3 Effect Modifier). The 
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subsequent analysis was conducted on each dataset, and results were pooled across sets 
(see 2.3.4 Model Estimation).  
 4.2.3.3 Analytic Model. The conditional probability of drug use as a function of 
age was estimated using Bayesian multi-level logistic regression models. Age was 
modeled using a 3-degree natural cubic spline with knots at 44 and 53 years to separate 
age tertiles. Models were adjusted for all confounders. Participant-specific intercepts 
(also known as random intercepts) were included, to account for the correlation between 
responses from the same participant.  
 To assess the effect of childhood adversity, the model above was extended by 
including an interaction term between each age spline term and each childhood adversity 
tertile. The fit of models with and without interaction effects were compared using WAIC 
(Vehtari, Gelman, & Gabry, 2017), to ensure inclusion of the interaction term improved 
expected out-of-sample predictive accuracy. 
 Bayesian models require specification of a prior distribution for parameters. We 
used non-informative priors: improper flat priors for all regression coefficients; a t-
distribution with mean 0, variance 10, and three degrees of freedom for the grand mean 
of the participant-specific intercept; and a half-t-distribution with mean 0, variance 10, 
and three degrees of freedom for the variance of the participant-specific intercept. These 
are the defaults for the modeling software used and are consistent with our lack of prior 
knowledge about model parameters given the novelty of this study.  
4.2.4.4 Model Estimation. Posterior distributions for all model parameters were 
estimated with Markov Chain Monte Carlo (MCMC) simulation using the modified 
Hamiltonian Monte Carlo “No U-Turn Sampler” (Hoffman & Gelman, 2014). In each of 
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the five imputed datasets, two Markov chains with different starting values were 
executed, for a total of 10 chains. Each chain contained 1,000 samples, half of which 
were thrown away as a “warm-up” period. For each parameter, chains were compared 
using the R-hat scale reduction statistic to assess model convergence (Stan Development 
Team, 2018). Chains were then pooled into 5,000 MCMC draws that were used to 
summarize the posterior distribution. 
4.2.4.5 Model Interpretation and Inference. Because age is modeled using 
natural cubic splines, it is impossible to interpret model coefficients directly. Instead, 
post-hoc calculations are required to answer the scientific question of interest. By 
transforming linear combinations of coefficients, we calculated:  
1. The predicted probability of drug use at each year of age for each level of 
childhood adversity, for a male Black participant (the most common 
demographic), recruited in a post-1988 cohort and attending a study visit in 
2010 (to make estimates more representative of present day) and a random 
intercept of 0.  
2. The relative odds of drug use at each age comparing a participant with high 
childhood aversity (5 or more adversities) to a participant with low childhood 
adversity (1 or 0 adversities). 
This calculation was conducted for each of the 5,000 MCMC draws to produce a 
full posterior distribution for all predicted probabilities and odds ratios. To summarize 
these distributions, we use the posterior median as a point estimate and the 0.025 and 
0.975 quantiles as bounds of a 95% Bayesian credible interval – in other words, there is a 
95% chance the probability/odds ratio falls in that interval. 
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4.2.4.6 Software. All analyses were conducted in R version 3.4.3 (R Core Team, 
2017). Multiple imputation was conducted using the ‘mice’ package (van Buuren & 
Groothuis-Oudshoorn, 2011). Bayesian models were estimated using the ‘brms’ package 
(Buerkner, 2016), which relies on Stan, a language for Bayesian modeling with 
Hamiltonian Monte Carlo sampling (Carpenter et al., 2017). 
4.3. Results 
4.3.1 Demographics and Childhood Adversity 
Of 352 participants, 69% were male, 82% were Black, and 73% joined the 
ALIVE cohort after the initial 1988 recruitment.  
The mean number of adverse childhood experiences reported was 4, and 80% of 
the sample reported at least 1 of the 14 adverse experiences. The most common adversity 
was growing up in a violent neighborhood (52.3%) followed by growing up in poverty 
(41.2%), and the loss of a parent (37.7%).  
4.3.2 Drug Use.  
4.3.2.1 Heroin. Heroin use was reported at 40% of all study visits. Heroin use 
was reported at 39% of all study visits from participants who reported 0 or 1 adverse 
childhood experience, 38% of study visits from participants who reported 2 to 4 adverse 
experiences, and 43% of study visits from participants who reported five or more adverse 
experiences.  
 4.3.2.2 Cocaine. Cocaine was reported at 45% of study visits. Cocaine use was 
reported at 43% of study visits from participants who experienced 0 or 1 adverse 
childhood experience, 42% of visits from participants who experienced 2 to 4 adverse 
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experiences, and 48% of visits from participants who reported 5 or more adverse 
experiences. 
4.3.3 Effect of Childhood Adversity 
 4.3.3.1 Heroin. In a model not accounting for childhood adversity, the predicted 
probability of heroin use declined from 80.5% (95% CI 69.8% to 88.1%) at age 35 to 
61% (95% CI 49.6% to 71.9%) at age 45, 33.0% (95% CI 23.9% to 42.6%) at age 55, and 
16.9% (95% CI 10.4% to 26.0%) at age 65. Adding terms for the interactions of age 
spline with childhood adversity improved model predictive accuracy (Null WAIC = 
6,671; Extended WAIC = 6,589). There were essentially no differences between the 0-to-
1 adversity group and the 2-to-4 adversities group. When comparing the 5-or-more 
adversity group to the 0-to-1 adversity group, the odds of heroin use were lower in the 5-
or-more group at age 35 (OR 0.39, 95% CI 0.17 to 0.88); this gap narrowed quickly and 
reversed, so that by age 65 heroin use was much more likely in the 5-or-more group (OR 
10.71, 95% CI 3.81 to 32.8). 
 4.3.3.2 Cocaine. In a model not accounting for childhood adversity, the predicted 
probability of cocaine use declined from 80.9% (95% CI 70.0% to 88.3%) at age 35 to 
64.5% (95% CI 53.3% to 74.3%) at age 45, 32.2% (95% CI 23.9% to 42.2%) at age 55, 
and 14.4% (95% CI 8.9% to 22.5%) at age 65. Adding terms for the interactions of age 
spline with childhood adversity improved model predictive accuracy (Null WAIC = 
6676; Extended WAIC = 6639). There were essentially no differences in between the 0 to 
1 adversity group and the 2 to 4 adversities group. When comparing the 5-or-more 
adversity group to the 0-to-1 adversity group, the odds of cocaine use were lower in the 
5-or-more group at age 35 (OR 0.69, 95% CI 0.31 to 1.53); this gap narrowed quickly 
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and reversed, so that by age 65, cocaine use was much more likely in the 5-or-more group 
(OR 15.57, 95% CI 5.15 to 45.92). 
4.4 Discussion 
 As expected, childhood adversity was very common among Baltimore city adults 
with a history of drug use. Eight out of ten study participants reported at least once 
adverse experience. By contrast only four out of ten members of a representative sample 
of the Maryland adults who participated in the 2015 Behavioral Health Risk Factor 
Surveillance System (BRFSS) survey reported at least one adverse experience (Maryland 
Behavioral Risk Factor Surveillance System, 2017). This wide gap in part reflects that 
our study questionnaire assessed for four additional types of adversity, including 
childhood poverty, bullying, social isolation, and neighborhood violence that were not 
included in the Maryland questionnaire, and that were among the most frequently 
reported by ALIVE participants. However, even if those four items are excluded, seven 
out of ten ALIVE participants report at least one adversity. These descriptive results are 
consistent with a robust literature finding that a history of adversity and trauma are 
common among adults who use drugs (Hughes et al., 2017).  
 Further, these results offer new evidence that past experiences of childhood 
adversity have a lasting impact on the course of heroin and cocaine use for people who 
have injected drugs. Indeed, these effects last decades into adulthood. These findings are 
novel. Other studies, noted in the Introduction, focused on the association of childhood 
adversity with snapshots of drug use at a single point in time. Therefore, past research 
could indicate that adversity either increases risk for the onset of substance use problems, 
or that childhood adversity increases the duration and severity of substance use problems. 
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By following the use behaviors of a cohort of people who have all used drugs over a 
period of 30 years, this study is to my knowledge the first to show that, even among 
people who are already using heroin and cocaine, childhood adversity continues to 
modify the course of use over many years of life. 
 Moreover, we found that, among people recruited for a study based on their past 
injection drug use, childhood adversity was primarily associated with elevated risk for 
heroin and cocaine use later in life. When participants were in their thirties, the 
probability of heroin and cocaine use was very high across all groups. However, over 
time, this risk declined sharply for adults who experienced fewer than 5 childhood 
adversities. By contrast, for adults who experienced five or more childhood adversities, 
risk for both heroin and cocaine use never declined much below 50 percent even as 
participants reached their late 50s and early 60s. This suggests that a history of 
substantial childhood adversity is an impediment to recovery.  
Notably, this delayed effect of childhood adversity is the opposite of our hypothesis 
that the effects of adversity would erode over time. Understanding why the effects of 
childhood experiences intensify over time is an essential question for future research. 
While we can only speculate, several hypotheses seem worthy of examination: 
 One possibility is that childhood abuse and trauma result in the development of  
maladaptive attachment styles that impede the formation and maintenance of healthy 
interpersonal relationships in adulthood (McCarthy & Taylor, 1999). Peer support has 
long been a part of the path to recovery from substance use problems (Tracy & Wallace, 
2016). Further, multiple studies have found that maladaptive attachment styles are 
common in people with substance use problems, and are associated with greater 
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psychopathology in that population (Diaz, Horton, & Malloy, 2014; Rick, Vanheule, & 
Verhaeghe, 2009; Thorberg & Lyvers, 2006). In addition, animal studies and brain-
imaging studies have indicated a role for mu-opioid receptors in the biology insecure 
attachment, and those same systems play an important role in the biology of addiction as 
well (Nummenmaa et al., 2015; Renk et al., 2015). Taken together, these studies suggest 
a mechanism whereby the childhood adversity impairs the formation of trusting and 
supportive informal relationships needed to facilitate recovery, or possibly impede 
formation of more formal relationships in the context of treatment. 
A second possibility is that, as noted, a history of child abuse is linked to a wide 
range of physical health problems (Anda et al., 2006), and in particular to chronic pain 
(Davis et al., 2005). It may be that, for people who have a history of high childhood 
adversity, heroin or cocaine use are means of compensating for these health problems and 
associated pain; so long as these related physical health problems remain, use continues 
and recovery is impeded. 
A third possibility is that very high levels of childhood adversity might cause other 
negative outcomes that inadvertently protect against substance use. For example, a 
history of childhood adversity is associated with adolescent and adult criminal behavior 
(Baglivio et al., 2014; Reavis, Looman, Franco, & Rojas, 2013). If participants 
experiencing the highest levels of adversity are regularly in and out of jail, this could 
reduce heroin or cocaine use in the six months prior to an ALIVE study visit simply 
because a substantial portion of time is spent incarcerated. Since criminal behavior 
declines dramatically as adulthood advances (Ulmer & Steffensmeier, 2014), effects of 
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childhood adversity on drug use in a cohort where drug use is common may only emerge 
in older age. 
Finally, a fourth possibility is that exposure to childhood adversity and adult drug use 
share common genetic risk. While seemingly counterintuitive, there is actually substantial 
evidence that genes influence children’s exposure to maladaptive parenting behaviors – 
this happens because genetically influenced characteristics like appearance, temperament, 
and impulse control  in turn influence how parents and other adults treat children 
(Baglivio et al., 2014; Reavis, Looman, Franco, & Rojas, 2013). It may be the study 
participants who have the highest genetic predisposition for impulsivity or antisocial 
behavior were both at high risk for exposure to childhood adversity and high risk for 
adult heroin and cocaine use because of these genes. 
These explanations are neither exhaustive nor mutually exclusive. However, 
regardless of the cause, the findings of this study have important implications for the 
treatment of heroin and cocaine use disorders. Specifically, they suggest that high levels 
of childhood trauma may play an increasingly important role in unremitting or relapsing 
cases of substance use disorder. To meet the needs of these most challenging clients, it 
will be important to develop, adopt, and evaluate programs that address the lasting 
psychological, behavioral, and physical impacts of childhood adversity and trauma. 
Indeed, the existing body of adverse childhood experiences research has launched a 
growing movement to try to promote “trauma-informed practice” within healthcare and 
other social service settings (Ko et al., 2008; Muskett, 2014). Indeed, the Substance 
Abuse and Mental Health Administration (SAMHSA) identifies six principles that trauma 
informed care should address: safety; trustworthiness and transparency; peer support; 
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collaboration and mutuality; empowerment; voice and choice; and cultural, historical, and 
gender issues (National Center for Trauma-Informed Care and Alternatives to Seclusion 
and Restraint, 2018). However, there is widespread confusion about how to incorporate 
these principles into behavioral health practice, and few studies examining whether 
“trauma-informed” programs offer superior care (Muskett, 2014). This is an important 
area for future research. In the meantime, given the urgency of the present opioid crisis, 
the results of this study suggest that testing and adoption of trauma-informed practice in 
substance use treatment is a worthy and urgent public health goal.  
Finally, two unusual findings should be noted. First, unlike Felitti and colleagues 
(Felitti et al., 1998), we did not observe a dose-response relationship between adversity 
and health – instead, low- and moderate adversity groups exhibited comparable 
probabilities of heroin and cocaine use over the life course, with only the high-adversity 
group diverging. Second, we found that, in early adulthood, a history of adversity 
appeared to protect against heroin use. We suspect the latter finding is spurious, since no 
similar association was seen for cocaine use.  However, another possibility, noted above, 
is that very high levels of childhood adversity also increase risk for the competing 
outcome like incarceration or institutionalization, which could prevent drug use at least 
temporarily. As for the former, more research is needed to understand if there is either a 
threshold effect of adversity, if it is only the presence of particular adverse experiences 
that lead to sustained heroin and cocaine use, or we simply had insufficient power to 
detect the smaller effect of fewer adversities. 
This study has a number of limitations. 1) The sample size – 352 participants 
contributing 8,013 visits – is small, especially considering the inclusion of interaction 
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effects and the need to use a flexible function to model the effects of age. Data collection 
is ongoing, and we intend to repeat this analysis with a larger sample, to solidify 
conclusions and reduce estimation uncertainty. 2) The study focuses on only two drugs – 
heroin and cocaine. Unfortunately, other opioid drugs such as prescription pain-relievers 
and fentanyl were not assessed for much of the observation period. Our necessary focus 
on heroin and cocaine limits the extent findings can be generalized to adults struggling 
with the current opioid epidemic. However, data collection about other opioid drugs is 
also now ongoing, and may be a focus of future analyses. Future research should also 
examine use of legal but dangerous substances like alcohol and tobacco. 3) This mostly 
male, mostly African American, almost exclusively urban, east-coast cohort – many of 
whom came of age during the peak of the HIV epidemic – are very different from the 
general population of drug users. In particular, there is an urgent need for research on 
rural substance use – the effects of adversity on use may be very different in rural 
communities, where treatment availability is scarce (Jones, Campopiano, Baldwin, & 
McCance-Katz, 2015). 4) ALIVE participants are also unique in that they were recruited 
because they had a history of injecting drugs. Injection drug use may be a marker for 
severity of drug-related problems; different effects of adversity might be observed in the 
broader cohort of adults who use heroin or cocaine but have never injected. 5) Childhood 
adversity was assessed retrospectively. If active drug use is differentially associated with 
differential recall of childhood experiences, then results could be biased. 6) Sixth, the 
childhood adversity questionnaire used is not the most widely used version assessment, 
and not the one used in the Maryland BRFSS. We chose this questionnaire because were 
seeking comparability with another large Baltimore cohort study, but that study 
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ultimately decided not to assess childhood adversity after our data collection had already 
begun. Unfortunately, we are therefore limited in our ability to compare study results to 
other populations. 6) Sixth, random intercept models are unbiased if study visits excluded 
for missing data are either “missing completely at random” or “at random,” but not if 
visits are missing “not at random.” (Rubin, 1976). If, for example, participants were more 
likely to miss study visits or not report information at times when they were also more 
likely to be using heroin or cocaine, then estimates would be biased. 7) Finally, the 
requirement that we report items indicating a history of child abuse to the department of 
social services – and the need to notify participants of that requirement – may have led to 
an undercount of the number of participants who actually experienced childhood abuse. 
4.5 Conclusion 
This study is, to our knowledge, the first to examine the effects of childhood 
adversity on risk for heroin and cocaine use over an extended period of life in a 
population where illicit substance use is endemic. We show that the effects of high 
adverse childhood experience persist into late adulthood, and impede cessation of heroin 
and cocaine use. Future research is warranted to examine the biological and 
psychological mechanisms behind these long-lasting effects. Further, these findings 
suggest that past traumatic experiences are an important target for substance use 
treatment programs, and that explicitly attempting to address the immediate and long-
term consequences of trauma may help facilitate recovery for some of the most persistent 
users of heroin and cocaine.  
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Table 4.1. Adverse Childhood Experiences and Demographics of Baltimore City 
Adults who Have Injected Drugs  
Demographic/Adversity Prevalence 
Sample Size 352 
Female 31.0% 
Black 82.4% 
Recruited > 1988 73.3% 
Emotional Neglect 27.2% 
Physical Neglect 15.9% 
Lost Parent 37.7% 
Domestic Violence at Home 24.1% 
Household Member Drug Use 36.5% 
Household Member Mental Illness 26.3% 
Household Member Incarcerated 28.8% 
Peer Bullying 22.8% 
Social Isolation 29.8% 
Neighborhood Violence 52.3% 
Poverty 41.2% 
Emotional Abuse 20.2% 
Physical Abuse 20.8% 
Sexual Abuse 17.8% 




Table 4.2. Heroin and Cocaine Use and Characteristics of Baltimore City Adults 
who Have Injected Drugs, by History of Adverse Childhood Experiences 
Outcome/Characteristic All 0-1 Adversities 2-4 Adversities 5+ Adversities 
Study Visits 8013 2770 2520 2723 
Heroin 39.9% 38.5% 38.0% 43.3% 
Cocaine 44.5% 43.3% 42.3% 47.7% 
Female 29.1% 30.5% 19.2% 36.7% 
Black 92.9% 92.4% 94.7% 91.9% 
cohort 48.5% 50.2% 51.1% 44.5% 
Visit -- 1980s 1.6% 1.9% 1.3% 1.7% 
Visit -- 1990s 21.1% 21.6% 20.4% 21.3% 
Visit -- 2000s 32.4% 32.6% 33.5% 31.2% 
Visit -- 2010s 44.9% 43.8% 44.8% 45.9% 
 Note: Counts and percents estimated from the average of 5 imputed datasets. 
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Table 4.3. Estimated Mean Predicted Probability and Relative Odds of Heroin and Cocaine Use by Age and History of 
Adverse Childhood Experiences 
Age 0-1 Adversities 2-4 Adversities 3-5 Adversities 
 Probability Odds Ratio v 0-1 Probability Odds Ratio v 0-1 Probability Odds Ratio v 0-1 
Heroin       
35 87% (76.3% - 93.6%) 1 (1 - 1) 86.7% (75.4% - 93.4%) 0.97 (0.42 - 2.23) 72.4% (55.3% - 84.9%) 0.39 (0.17 - 0.88) 
45 62.9% (47.7% - 77%) 1 (1 - 1) 62.4% (46.7% - 75.9%) 0.97 (0.44 - 2.11) 62% (45.4% - 76.3%) 0.95 (0.46 - 2.06) 
55 22.3% (13.8% - 34.6%) 1 (1 - 1) 31.1% (19.7% - 45.3%) 1.56 (0.72 - 3.46) 48.1% (32.8% - 64.4%) 3.23 (1.51 - 7.08) 
65 9.1% (4.2% - 18%) 1 (1 - 1) 7.9% (3.5% - 16.7%) 0.87 (0.3 - 2.59) 51.7% (30.4% - 72.5%) 10.71 (3.81 - 32.8) 
Cocaine       
35 83.7% (70.9% - 91.9%) 1 (1 - 1) 82.2% (69.4% - 90.6%) 0.89 (0.4 - 2.03) 78% (63.4% - 88.5%) 0.69 (0.31 - 1.53) 
45 65.3% (49.6% - 79%) 1 (1 - 1) 68.8% (54.5% - 80.7%) 1.16 (0.56 - 2.54) 60% (44.2% - 75.1%) 0.8 (0.37 - 1.72) 
55 26.6% (16.3% - 40.5%) 1 (1 - 1) 33% (21.6% - 47.6%) 1.36 (0.64 - 2.97) 37.6% (24.4% - 54.3%) 1.68 (0.78 - 3.71) 
65 4.6% (2.1% - 10%) 1 (1 - 1) 15.4% (7.3% - 29%) 3.73 (1.26 - 11.36) 43.1% (23.8% - 64.1%) 15.57 (5.15 - 45.92) 
Note: Predictions for hypothetical male, Black participant, recruited in a post-1988 cohort, attending a study visit in the 2010s, with a 
random intercept of 0. 
Note: Estimates based on average of 5 imputed datasets. 





Figure 4.1 Estimated Predicted Probability of Heroin and Cocaine Use at Ages 30-
65 by Exposure to Adverse Childhood Experiences in Baltimore Adults who 
Injected Drugs 
 
Note: Predictions for hypothetical male, Black participant, recruited in a post-1988 
cohort, attending a study visit in the 2010s, with a random intercept of 0. 




CHAPTER 5. VALIDATING BAYESIAN INTERRUPTED TIME-SERIES 







Background: In 2011, Florida established a Prescription Drug Monitoring 
Program and adopted new regulations for independent pain-management clinics. This 
chapter presents a method for examining the effects of those reforms on health outcomes 
in Florida, using the example of drug overdose deaths and other injury fatalities.  
Methods: Florida’s post-reform monthly mortality rates – for drug-involved 
deaths, motor vehicle crashes, and suicides by means other than poisoning – were 
compared to a counterfactual estimate of what those rates would have been absent 
reform. The counterfactual was estimated using a Bayesian structural time-series model 
based on mortality trends in similar states. 
Results: By December 2013, drug overdose deaths were down -17% (95% CI, -
21% to -12%), motor vehicle crash deaths were down -9% (-14%, to -4%), and suicide 
deaths were unchanged compared to what would be expected in the absence of reform. 
 Conclusion: Florida’s opioid prescribing reform substantially reduced drug 
overdose deaths. Reforms may also have reduced motor vehicle crash deaths but had no 
effect on suicides; more research is needed to understand these patterns. Bayesian 
structural time-series modeling can be used for studying the effects of Florida’s 




5.1.1 Florida Reforms Targeting Opioid Prescribing 
Opioid overdose deaths in Florida consistently exceeded the national average 
from the 1990s into the late 2000s (National Institute on Drug Abuse, 2018). Identifying 
problematic opioid prescribing as a possible driver of these high overdose rates, in 2010-
2011, Florida adopted a number of reforms to try to reduce prescription drug-related 
mortality.  
First, Florida’s legislature authorized the creation of a prescription drug 
monitoring program (PDMP). All prescribers of controlled substances were required to 
check the PDMP to review each patient’s prescription history before prescribing a 
controlled substance, and log each prescription made in the PDMP. The law also allowed 
certain investigators from law enforcement and health agencies to access the PDMP (Gau 
et al., 2017). 
Second, Florida’s legislature officially defined “pain management clinics” to be 
programs that either advertised themselves as such or had a majority of their patients 
receiving pain medication. Florida required these programs to register with the state. 
Then, beginning July of 2011, Florida’s adopted a “pill mill” law. This law required 
physician ownership of pain-management clinics, prohibited these clinics from operating 
onsite pharmacies, and permitted opioids to be prescribed only if the prescription was 
accompanied by a medical exam and follow-up care (Gau et al., 2017). 
Following the adoption of these reforms, more than 500 of Florida’s 900 
independent pain management clinics closed (Gau et al., 2017). Opioid prescriptions fell 
as compared to other, similar states, with the largest reductions seen among doctors 
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making the highest volume of prescriptions and patients receiving the highest volume of 
prescriptions (Rutkow et al., 2015). Oxycodone overdose deaths fell sharply (Delcher, 
Wagenaar, Goldberger, Cook, & Maldonado-Molina, 2015), even as they continued to 
increase in nearby North Carolina (Kennedy-Hendricks et al., 2016). 
Taken together, these studies suggest that Florida’s policy changes were, at least 
initially, effective at achieving their primary objective – preventing unsafe opioid 
prescribing. There is also evidence that overdose deaths declined as a result of these 
measures.  
5.1.2 Secondary Effects of Florida Policy on Other Injury Deaths 
While overdose deaths have been the subject of past research, the effects of 
Florida’s opioid prescribing reforms may not end at overdose deaths.  
Opioid use can induce drowsiness and impair cognitive function (Altilio et al., 
2007). This could increase risk for car crashes. In fact, opioid use is associated with 
unsafe driving behavior among people involved in motor vehicle crashes (Dubois, 
Bédard, & Weaver, 2010). Further, among people drug-tested following motor vehicle 
crashes, the proportion identified as having used opioids has increased over the last 
decade (Governors Highway Safety Assocation, 2018). However, at least one literature 
review found no evidence that opioid use was associated with motor vehicle crashes. 
(Fishbain, Cutler, Rosomoff, & Rosomoff, 2002).  
Further, some critics of restrictions on opioid prescribing argue that crackdowns 
on opioid prescribing may lead to poor management of chronic pain and, in some cases, 
increased risk for suicide (Levine, 2018). Chronic pain is associated increased risk for 
suicide attempt and completion (Racine, 2018), and very high rates of suicidal ideation 
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and attempt have been found among veterans whose physicians terminated their 
prescription opioid use (Demidenko et al., 2017). 
In summary, in addition to drug overdose deaths, it is plausible that Florida’s 
opioid crackdown might have affected rates of death from motor vehicle crash and 
suicide. To date, no studies have examined the effect of Florida’s opioid prescribing 
reforms – or any other legal intervention targeting opioid prescribing – on these other 
possible sources of injury mortality. 
5.1.3 Motivation and Hypotheses 
 This study examines the effect of Florida’s PDMP and pill mill laws on mortality 
in Florida. Past research on mortality trends following Florida’s prescribing reforms has 
focused only on mortality from drug overdoses. Those analyses have also been limited by 
the absence of a strong control group – studies relied either on a single comparison state 
(Kennedy-Hendricks et al., 2016) or included no comparison state at all (Delcher et al., 
2015). Here, we first seek to replicate the finding that drug overdose deaths declined 
dramatically following Florida’s prescribing reform using Bayesian structural time series 
models (BSTS), a relatively new approach to interrupted time series that allows for the 
inclusion of multiple states and allows for adjustment for local or seasonal trends 
observed in the pre-intervention period. Next, we extend those results to two other 
possible causes of mortality that could be affected by prescribing reforms – motor vehicle 
crashes and suicide deaths not caused by poisoning. As a control, we also examine the 
effect of Florida’s reform on two causes of mortality – major cardiovascular diseases and 
malignant neoplasms – that should not be affected. 
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We hypothesize that, in the two-and-a-half years following Florida’s prescribing 
reforms, drug overdose and motor vehicle crash deaths all declined, but suicide deaths 
increased, relative to what would have occurred had Florida not instituted any reforms. 
We hypothesize no change the control outcomes, heart disease or cancer. 
 In the context of this dissertation, a secondary goal of this study is to demonstrate 
the utility of a new approach to analyzing interrupted time series data – Bayesian 
structural time series. By replicating the previously demonstrated reduction in opioid 
mortality following Florida’s prescribing reforms, we establish the utility of this method 
for seeing if Florida’s prescribing reform had the unintended benefit of reducing 
substantiated child maltreatment (Chapter 6). 
5.2 Methods 
5.2.1 Data 
 Monthly mortality counts were extracted for Florida and all states using data from 
publicly available counts published through the CDC’s online WONDER database. 
(Centers for Disease Control and Prevention, National Center for Health Statistics., 
2017). The WONDER database can be found at https://wonder.cdc.gov/. Drug overdose 
deaths include all deaths where the underlying cause of death was determined to be drug-
related. Note that this could include accidental overdoses, suicides, or homicides. Suicide 
deaths included all injury deaths where the injury intent was determined to be suicide, 
excluding deaths where the mechanism of injury was poisoning. Poisoning deaths were 
excluded to distinguish this outcome from the drug overdose deaths outcome and isolate 
suicide deaths that were not caused by drug overdose (but see 2.3.7 “Sensitivity 
Analysis”). Motor vehicle crash, as well as the two control outcomes major 
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cardiovascular disease and malignant neoplasm deaths, each included all deaths in the 
corresponding “113 Causes of Death” type. To compute monthly mortality rates, these 
counts were divided by annual average population totals taken from U.S. Census 
intercensal estimates of the population of each state. These estimates can be found on the 
Census bureau’s FTP site (https://www2.census.gov/programs-surveys/popest/).  
5.2.2 Study Sample 
The time period for this study is January, 2005 through December, 2013. Twenty-
three states were selected as possible states because they already had some type of PDMP 
law in place as early as 2005. These states were identified using the Law Atlas project 
from the Policy Surveillance Program at Temple University School of Law (NPO Staff, 
2018). Restricting states to states with a PDMP in 2005 was necessary because, in order 
to serve as comparisons, states could not have made a similar policy change to Florida 
(see the “Assumptions” section). (We considered using states that did not have a PDMP 
for the entire observation period as comparison states; it turned out that there were no 
states that met this criterion.).   
The CDC suppresses the monthly mortality count for each state reporting fewer 
than 10 deaths in that month. For this reason, in the analysis of each cause of death, some 
of the 23 eligible comparison states were not actually included as comparisons because at 
least one of their mortality totals was suppressed. The exact comparison states included in 
each analysis are shown in Table 1. Every analysis had at least 17 comparison states. 
5.2.3 Analytic Approach 
 The goal of the analysis is to determine how different Florida’s mortality rate for 
each cause of injury mortality would have been had it not adopted the opioid prescribing 
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reforms described above (hereafter the “intervention”). The analytic approach is the same 
for all mortality measures, so from here we refer generally to the “mortality rate.” We can 
only observe Florida’s behavior in the presence of the intervention, so the goal is to 
estimate Florida’s behavior in the absence of intervention. There are three natural 
approaches to estimating how Florida would have behaved in the post-intervention 
period: 1) we could extrapolate from Florida’s behavior in the pre-intervention period; 2) 
we could infer Florida’s behavior in the post-intervention period from other states that 
behaved similarly in the pre-intervention period; and 3) we could use our prior 
assumptions about how Florida should have behaved in the post-intervention period 
(Brodersen, Gallusser, Koehler, Remy, & Scott, 2015). We adopt the approach described 
by Brodersen and colleagues (Brodersen et al., 2015), and combine all three sources of 
information using a method known as Bayesian Structural Time Series (BSTS) models to 
forecast Florida’s behavior in the absence of the intervention. By taking the difference 
between our forecast and the observed value, we estimate the effect of the intervention.  
Below, we briefly describe BSTS models and describe their application to the 
problem at hand. BSTS models are described elsewhere in detail (Brodersen et al., 2015; 
Scott, 2017; Scott & Varian, 2014) 
 5.2.3.1 Brief Background on Bayesian Modeling. All Bayesian models have 
three components: 1) a “prior” probability distribution that quantifies existing beliefs 
about each parameter of interest before data are collected; 2) a “likelihood” that 
quantifies the probability of the observed data given the parameters of interest; and 3) a 
“posterior” distribution that combines the prior and the likelihood using Bayes’ theorem 
to combine information (from the prior and the data) about each parameter of interest. 
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Inference is made by summarizing the posterior distribution – for example, instead of a 
traditional frequentist “point estimate” of a parameter, a Bayesian estimate might be the 
mean (or median) of the posterior distribution for that parameter. Bayesian methods 
allow for extremely flexible interpretation of model parameters because, so long as we 
can sample from the posterior distribution of model parameters, we can also estimate the 
posterior for any arbitrary combination of those parameters through Monte Carlo 
simulation. In practice, it is often impossible to sample directly from the posterior 
distribution, in which case Markov Chain Monte Carlo (MCMC) methods are used to 
sample indirectly. In this analysis, each time we fit a model, we went through 10,000 
MCMC iterations to estimate the posterior. For an introduction to Bayesian methods, see 
van de Schoot and colleagues (van de Schoot et al., 2014).  
 5.2.3.2 Bayesian Structural Time Series Models (BSTS). BSTS use the 
flexibility of Bayesian model averaging to combine a number of different time series 
models into a single forecast. In this analysis, we average two simple models for 
Florida’s behavior in the post-intervention period:  
1. The first is a seasonal model, where Florida’s mortality rate is modeled using a 
dummy variable for three-month periods (e.g., Jan-Mar, Apr-Jun, etc).  
2. The second is a “spike-and-slab” linear regression model (Ishwaran & Rao, 
2005), where Florida’s mortality rate in each month of the pre-intervention period 
is regressed on the mortality rate in the comparison states. Spike-and-slab 
regression is a machine-learning approach similar to lasso or ridge regression that 
uses “shrinkage” to down-weight covariates that do less to improve predictive 
 123 
accuracy, reducing model variance and improving out-of-sample predictions as 
compared a simple linear regression (Ishwaran & Rao, 2005).  
The averaged model is then used to generate regression predictions of Florida’s 
mortality rates in the post-intervention period based on seasonal trends and the behavior 
of the comparison states in the post-intervention period. 
 5.2.3.3 Model Fitting. Bayesian models require specification of a prior for all 
parameters. To all regression coefficients, seasonal dummy variables, and residual 
variances, we assign so-called “non-informative” prior distributions, a common default 
choice in Bayesian analysis, and the default in the modeling package used (see 
“Software”). These are consistent with the fact that we have essentially no a priori 
knowledge as to what these parameters should be. The spike and slab model also requires 
a meta-parameter – the “expected model size” – to be chosen. We chose an expected 
model size of 1. This technically corresponds to a prior belief that there is a 1/n 
probability that each regressor is predictive of the mortality rate in Florida; more 
practically, the prior functions as a form of “shrinkage” to reduce model variance and 
improve accuracy similar to a “lasso” or “ridge regression.” This is a conservative prior 
choice, because it does presume any state is more or less predictive, and is the default for 
the modeling package used (see “Software”).  
5.2.3.4 Effect Estimation. We fit a BSTS to forecast Florida’s mortality rate in 
the post-intervention period. For each MCMC iteration, for all months in the post-
intervention period, we convert predicted rates into counts and take the difference 
between the observed death count and the model-estimated death count – this is an 
estimate of the effect of the intervention in that month. In addition to these monthly 
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estimates, we add the model-estimated monthly count to the model-estimated count in all 
prior months, and take the difference between this model-estimated value and observed 
value – this is an estimate of the cumulative effect of the intervention up to that month. 
Taking the mean and 0.025 and 0.975 quantiles of these posteriors give point estimates 
and 95% Bayesian credible intervals for the effect of the intervention up through each 
post-intervention point. 
5.2.3.5 Model Checking and Inference. The analysis relies heavily on the 
assumption that any deviation between our forecast of Florida’s post-intervention 
mortality rate and its true post-intervention rate is attributable to the effect of the 
intervention, and not model mis-specification. We test the plausibility of this assumption 
two ways:  
First, we use a simplified version of the test proposed by Abadie and colleagues 
(Abadie et al., 2010). Specifically, we repeat the same analysis on each of the comparison 
states, and rank the estimated relative change in number of incidents in each state from 
the largest to the smallest magnitude. Since comparison states did not adopt any 
intervention during the observation period, estimated “intervention effects” should be 
zero in expectation, and much smaller than those observed in Florida. If intervention 
effects estimated in Florida are comparable in magnitude to those observed in the 
comparison states, then we would be concerned these effects are merely the result of 
random error or model misspecification. 
Second, we repeat the entire analysis for two causes of mortality that should not 
have been affected by Florida’s prescribing reform – major cardiovascular diseases, and 
malignant neoplasms. If the modeling approach cannot accurately predict post-
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intervention trends in these unaffected causes of death, then we would be concerned than 
any effects observed on the outcomes of interest were merely the result of the poor 
predictive accuracy of the model.  
5.2.3.6 Assumptions. The first important assumption underlying this analysis is 
that Florida’s PDMP and pill mill laws had no effect on the outcome in any comparison 
state (i.e., the Stable Unit Treatment Value Assumption, or SUTVA). This assumption 
could be violated if, for example, these laws reduced illegal trafficking of opioids from 
Florida to other states used as comparisons. The second assumption is that, had Florida 
not adopted its PDMP and pill mill laws, the association between mortality in comparison 
states and Florida before July 2011 would have remained the same after July 2011. This 
assumption would be violated if, for example, a comparison state adopted some other 
reform that caused its mortality rate to diverge from Florida’s.  
5.2.3.7 Sensitivity Analysis – Poisoning Suicide. As noted, the estimated suicide 
death rate excluded deaths caused by poisoning, which might be affected differently than 
other methods of suicide. As a sensitivity analysis, we repeated our analysis of suicides 
including all suicides, including poisoning. 
5.2.3.8 Software. All models were estimating using the “bsts” package in R (R 
Core Team, 2017; Scott, 2017). 
5.3 Results 
5.3.1 Drug Overdose 
Drug overdose deaths in Florida increased from 2005 into 2011, before declining 
by the end of 2013 (Table 2, Figure 1). As compared to the BSTS-estimated 
counterfactual estimates, by December of 2013, cumulative drug overdose deaths over 
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the full observation period were down by about a sixth (-16.8%, 95% Credible Interval -
21.3% to -11.7%) (Table 3, Figure 2). This corresponds to a reduction of 1,377 deaths, or 
an average of 86 deaths averted per month.  
5.3.2 Motor Vehicle Crash 
Motor vehicle crash deaths declined from 2005 into 2011, before increasing 
slightly by the end of 2013 (Table 2, Figure 1). As compared to the BSTS-estimated 
counterfactual estimates, cumulative motor vehicle crash deaths over the full observation 
period were down by about a tenth (-9.1%, 95% CI -14.4% to -3.5%) (Table 3, Figure 2). 
This corresponds to a reduction of 615 deaths, or an average of 38 deaths averted per 
month.  
5.3.3 Suicide 
Non-poisoning suicide deaths fluctuated over the study period (Table 2, Figure 1). 
As compared to the BSTS counterfactual estimates, suicides were essentially unchanged 
(0.4%, 95% CI -7.0% to 8.3%) (Table 3, Figure 2). Results of sensitivity analysis where 
poisoning suicides were included were the same (not shown). 
5.3.4 Model Checking 
 After repeating the analysis in all comparison states, the magnitude of the percent 
change in cause-specific mortality at 30 months in Florida was the third (out of 18) 
largest for drug overdose, third (out of 18) for motor vehicle crash, and 17th (out of 18) 
for suicide (Appendix Exhibits, Figures 1-4). In other words, the intervention effect in 
Florida on both drug overdose and motor vehicle crash death, but not suicide, was more 
extreme than “effects” observed by chance in most other states that did not actually 
implement any intervention (Table 3). 
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 Repeating the analysis for major cardiovascular disease and malignant neoplasm 
mortality showed no effect of prescribing reforms on these control outcomes (Appendix 
Exhibits, Figures 5 and 6).   
5.4. Discussion 
5.4.1 Drug Overdose Deaths 
Our analysis provides strong evidence that policies that reduce high-volume or 
insufficiently supervised opioid prescribing prevent drug overdose deaths. We find that 
drug overdose mortality declined sharply following the introduction for Florida’s opioid 
prescribing reforms, preventing 1,377 drug overdose deaths during the 30 months 
following of the introduction of the pill mill law. This is similar to the conclusions of 
Kennedy-Hendricks and colleagues (Kennedy-Hendricks et al., 2016), who analyzed a 
slightly different 34 month period and found reforms prevented 1,029 prescription opioid 
overdose deaths. Our analysis has a number of unique strengths: Our analytic approach 
combines information from 17 comparison states (instead of only one) and from seasonal 
patterns in the pre-intervention period to produce precise estimates. We also verify the 
predictive accuracy of our modeling approach in states that did not implement any 
intervention, and with other sources of mortality in Florida that should be unaffected by 
prescribing reforms. Finally, we include all drug overdose mortality, rather than trying to 
distinguish between sources of mortality, because there is evidence that incomplete 
cause-of-death reporting leads to undercounts of opioid-specific mortality (Buchanich, 
Balmert, Williams, & Burke, 2018). We find it encouraging that these two studies – 
which used different data sources and different analytic approaches – reached very 
similar conclusions.  
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It is important to note that we (and Kennedy-Hendricks et al.) ended our 
observation period at the end of 2013. Beginning in 2014, deaths from synthetic opioids 
such as fentanyl increased dramatically. Synthetics quickly became the leading cause of 
opioid overdose death, both in Florida and nationally, and annual drug overdose deaths 
more than doubled (National Institute on Drug Abuse, 2017). We cannot be sure that the 
benefits of Florida’s prescribing reforms were sustained in this new era of synthetic 
opioids. However, we find it encouraging that our monthly estimates (Figure 2) suggest 
that all drug overdose deaths were consistently down over our entire two-and-a-half-year 
study period – this suggests that prescribing reforms did not lead opioid users to 
immediately substitute other, illegal drugs. 
We should also note that our ecological approach does not provide any 
information about why Florida’s reforms were effective. Prescribing reforms could 
prevent mortality in a number of ways: by preventing accidental overdoses of people 
receiving an opioid prescription who have no addiction; by preventing accidental 
overdoses of people receiving an opioid prescription who misuse their drugs or have an 
addiction; by preventing the formation of new opioid addictions; by preventing drug-
induced suicide deaths; or by preventing diversion of drugs onto the black market. We 
also cannot determine who was affected by the reform – older or younger opioid users, 
men or women, or people living in urban or rural areas. Understanding who is affected 
and mechanism of action is essential to developing and targeting new policies that meet 
the needs of people who may not be benefitting from prescribing reforms; this is an 
important topic for future research. 
5.4.2 Other Sources of Mortality 
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In addition to drug overdose death, we were interested in how Florida’s 
prescribing reforms might have affected other causes of death that may be linked to 
opioid use. Our findings were mixed: 
Our model estimates an approximately 9 percent reduction in motor vehicle crash 
fatalities attributable to Florida’s prescribing reforms. This is consistent with our 
hypothesis that fewer opioid prescriptions would lead to less opioid-impaired driving. 
However, unlike drug overdose deaths – which fell almost immediately in the second half 
of 2011 – most of this reduction comes from lower than expected rates of motor vehicle 
crash death in 2013. We did not anticipate this delayed effect a priori. Further, we did not 
directly examine drug-impaired driving. Therefore, we would consider these findings 
preliminary, and believe they should motivate future research on opioids and driving. 
By contrast, we find no evidence that suicide mortality changed following 
Florida’s opioid prescribing reforms. This was true both of all suicides, and of all suicides 
other than poisonings. This is encouraging, because both medical organizations and the 
popular press have raised concerns that prescribing reforms may lead to increased suicide 
deaths among people whose pain was previously treated by opioids (Kertesz, Manhapra, 
Olivia, & Sandbrink, 2018; Levine, 2018). Opioid prescribing has declined across the 
country since 2011 (IQVIA, 2018), a process that has likely accelerated due to new CDC 
guidelines on opioid prescribing (Dowell, Haegerich, & Chou, 2016). While careful 
monitoring of these broader declines and of the appropriateness of CDC guidelines is 
needed, it is encouraging that, even after Florida’s dramatic reforms to opioid 
prescribing, suicide rates did not budge relative to other, similar states. 
5.4.3 New Methods for Interrupted Time Series 
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 In addition to substantive findings, this study presents an application of a 
relatively new analytic approach – Bayesian structural time series (BSTS) models for 
causal impact evaluation. Although BSTS models have been used in some public health 
settings (Bruhn et al., 2017), we believe these models are likely unfamiliar to many 
epidemiologists and wish to highlight some of their benefits and compare them to other 
approaches commonly used in epidemiology for causal impact evaluation: 
1. BSTS models improve predictive accuracy by combining information from trends 
in the target unit seen in the preintervention period with the observed behavior of 
other similar comparison units that did not receive the intervention in the post-
intervention period. This combines the strengths of two other common approaches 
to these problems – time series models like ARIMA, and difference-in-difference 
approaches like panel regression (Bernal, Cummins, & Gasparrini, 2017; Card & 
Krueger, 1994). 
2. BSTS models also improve predictive accuracy by not treating all comparison 
units as equally useful. Instead, BSTS uses “machine learning” (spike-and-slab 
regression) to place more weight on comparison units that best predict the 
behavior of the intervention unit in the pre-intervention period. 
3. By predicting post-intervention trends from the observed behavior of comparison 
units, BSTS models do not require any parametric assumptions about post-
intervention trends (e.g., that they will be linear or quadratic). 
4. Because BSTS models make predictions at every timepoint in the post-
intervention period, it is possible to accurately estimate a wide variety of effects 
that may be scientifically interesting. For example, we can estimate the effect of 
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the intervention in any particular month (e.g., Figure 2, left side) or the 
cumulative effect of the intervention up to any particular month (e.g., Figure 2, 
right side). 
5. BSTS models are Bayesian, which means that they produce a full posterior 
distribution for every estimated quantity. This also means that, for any effect we 
estimate, we can also construct a 95% interval of uncertainty. This is not true of 
some other more flexible interrupted time series designs like synthetic control 
methods (Abadie et al., 2010).  
6. Estimating the treatment effect in one unit based on other comparison units lends 
itself to a natural and transparent model-checking approach. Since comparison 
units implement no intervention, it should be possible to predict their behavior in 
the post-intervention period accurately. If predictions in comparison states are 
poor, then it is likely that estimated intervention effects are wrong. 
7. BSTS models are automated in a user-friendly R package (Scott, 2017). Further, 
although not used in this paper, interrupted time series analysis with BSTS is also 
automated in a user-friendly package (Brodersen et al., 2015). Both of these 
packages provide automated tools for visualizing models, which can help users 
make thoughtful modeling decisions, check that predictions are consistent with 
data, and present results in an intuitive format. 
The analysis above illustrates all of these properties and can serve as a model for a 
diverse array of epidemiologic investigations. 
5.4.4 Limitations 
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This analysis has a number of limitations. First, the main assumption of our 
analysis is that Florida’s PDMP and pill mill laws were the only state interventions that 
might have impacted the mortality rates analyzed here. We cannot know if some other 
policy change made in Florida or in one of the comparison states highly predictive of 
Florida’s pre-intervention trends is responsible for the effects described here. Second, 
mortality rates are estimated by dividing CDC reported monthly counts by census mean 
annual population estimates. Since the population changes over the course of the year, 
there is some error in these estimated rates, although likely very small. Third, this is an 
ecological study, and the outcome analyzed is a rate calculated at the state level – 
research on individuals is needed to determine the effects of reducing or eliminating 
opioid use on individual risk for the types of mortality examined here. 
5.5 Conclusion 
 The analysis presented here offers strong evidence that Florida’s opioid 
prescribing reforms sharply reduced drug overdose deaths over the thirty-month period 
following their introduction. It also offers comforting evidence that Florida’s suicide 
mortality rate did not change following these reforms. Finally, the analysis offers 
preliminary evidence that prescribing reforms may have reduced motor vehicle crash 
fatality – possibly because of reductions in opioid-impaired driving. These final two 
results merit further investigation with data collected from individuals who currently use 
or formerly used opioids. 
 For policy-makers, we think there are two clear implications. First, reforms that 
reduce irresponsible or unnecessary opioid prescribing prevent drug overdose deaths. 
States and the federal government should continue to promulgate regulations that reduce 
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prescribing of opioids and promote alternative treatment of chronic pain. Second, these 
reforms may have unanticipated consequences. In this study, we identified a possible 
positive unintended consequence – a reduction in motor vehicle crash deaths – without 
any negative unintended consequences – a change in suicide deaths. However, other 
reforms structured differently might have different effects on different outcomes. It will 
be important carefully monitor pain patients in locations instituting opioid prescribing 
reforms on multiple outcomes, to ensure that any reduced risk of overdose death is 
accompanied by overall reductions in morbidity and mortality risk. 
 For researchers, it will be important to understand who has been affected by 
Florida’s opioid prescribing reforms and why the law has been effective. The findings 
presented here also should remind researchers that it is important to examine not only the 
targeted outcome of drug control policies, but also secondary and possibly negative 
outcomes, to ensure the benefits of policy change outweigh the harms.  
Finally, the method we present here – BSTS for causal impact analysis – is an 
excellent tool for studying both the intended and collateral impacts of state-level drug 
policies. Interrupted time series analyses are plagued by contradictory or implausible 
findings. For example, two recent studies published within months of each other found 
large but opposite effects of laws permitting bystanders to carry naloxone on opioid 
misuse (Doleac & Mukherjee, 2018; Rees, Sabia, Argys, Latshaw, & Dave, 2017). 
Subsequent research suggests that naloxone use did not increase in these states following 
the introduction of these laws, making both findings implausible (Frank, Humphreys, & 
Pollack, 2018). We believe BSTS can help reduce these kinds of contradictory findings 
by forcing researchers to clearly display the results of their modeling in a way that is 
 134 
easily understandable to a general scientific audience – because it focuses on isolating the 
effect of a single intervention in a single state, because its results are easily visualized, 
and because it facilitates intuitive model-checking through repeated analysis of 
comparison states.   
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Table 5.1. Comparison States Included in Each Analysis 








AL X X X X X 
CA X X X X X 
CO X X X X X 
FL X X X X X 
HI    X X 
ID    X X 
IL X X X X X 
IN X X X X X 
KY X X X X X 
ME    X X 
MA X X X X X 
MI X X X X X 
NV X X X X X 
NM X X  X X 
NY X X X X X 
OH X X X X X 
OK X X X X X 
PA X X X X X 
RI    X X 
TX X X X X X 
UT X  X X X 
VA X X X X X 
WV  X X X X 
WY       X X 
Note: “X” indicates the state was included.  
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Table 5.2. Monthly Drug and Other Cause Mortality Rates and Counts Before and After Florida's Opioid Prescribing 










January, 2005 1.1 (197) 1.7 (310) 0.9 (156) 30.9 (5522) 19.2 (3417) 
July, 2011 1.4 (274) 1.1 (202) 1.1 (204) 22.3 (4254) 18.5 (3520) 
December, 2013 1.2 (233) 1.2 (232) 0.9 (182) 25.1 (4898) 18.5 (3618) 
 
Note: Rate is deaths per 100,000 residents per month.
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Table 5.3. Estimated Cumulative Percent Change in Mortality following Florida's Opioid Prescribing Crackdown, July 
2011-July 2014 
  
July, 2011 through  
December, 2011 
July, 2011 through  
December, 2012 
July, 2011 through  
December, 2013 
Drug Overdose -5.9% (-12.9% to 2.3%) -13.6% (-18.6% to -7.8%) -16.8% (-21.2% to -11.8%) 
Motor Vehicle Crash -5.6% (-15.5% to 5.7%) -6.2% (-12.5% to 0.6%) -9.1% (-14.5% to -3.6%) 
Suicide (non-poisoning) -0.3% (-9.8% to 10.7%) 0.2% (-8.5% to 9.4%) 0.4% (-7% to 8.3%) 
Major Cardiovascular Disease -1.2% (-4.7% to 2.6%) -0.4% (-2.7% to 2.2%) -0.7% (-2.7% to 1.7%) 
Malignant Neoplasm 0.3% (-1.8% to 2.4%) -0.2% (-1.5% to 1.1%) 0.1% (-1.1% to 1.3%) 
 
 Effects presented as: Estimate (95% Credible Interval)  
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5.8 Appendix Exhibits 
 
Figure 5.1a. Estimated Effect of Florida Opioid Prescribing Crackdown on Drug 








Figure 5.2a. Estimated Effect of Florida Opioid Prescribing Crackdown on Motor 
Vehicle Crash Deaths: Florida vs Comparison States 
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Figure 5.3a. Estimated Effect of Florida Opioid Prescribing Crackdown on Suicide 




Figure 5.4a. Estimated Effect of Florida Opioid Prescribing Crackdown on Major 
Cardiovascular Disease Deaths: Florida vs Comparison States 
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Figure 5.5a. Estimated Effect of Florida Opioid Prescribing Crackdown on 





CHAPTER 6. EFFECT OF FLORIDA’S OPIOID PRESCRIBING CRACKDOWN 





Background: Research shows increases in opioid misuse in a community are 
associated with concurrent increases in the number of children coming into contact with 
child protection. In 2011, Florida adopted a number of reforms that reduced problematic 
opioid prescribing and reduced overdose deaths. These reforms may have reduced child 
protection contact as well. 
Methods: Quarterly rates of substantiated child physical abuse, child sexual 
abuse, neglect, and foster care entry were calculated for each state using administrative 
records. Trends in each outcome in Florida before and after July 2011 were examined. 
Counterfactual trends after July 2011 in the absence of reform are estimated using the 
observed behavior of 12 control states with Bayesian Structural Time-Series Models. 
Results: Trends in all four maltreatment outcomes did not differ substantially 
from estimates of counterfactual trends in the absence of reforms.  
 Conclusion: We find no evidence that Florida’s opioid prescribing reforms 
reduced substantiated maltreatment or foster care entry. Future research should explore 
which substance use policies or programs are effective at preventing child maltreatment 
and other collateral harms to children.  





6.1.1 The Opioid Epidemic and Child Welfare. 
The United States is in the midst of a severe epidemic of opioid-related problems 
(Kolodny et al., 2015). As described in the introductory chapter, research suggests that 
opioid misuse by family, household, or community members is putting a growing number 
of children at risk for negative health or safety outcomes (Feder, Mojtabai, Musci, & 
Letourneau, 2018). As opioid related problems increase in a region, so do substantiated 
maltreatment cases (Ghertner, Baldwin, Crouse, Radel, & Waters, 2018), and intentional 
and unintentional injuries (Wolf, Ponicki, Kepple, & Gaidus, 2016). Increases in opioid 
prescriptions in a county have also been linked to increased rates of children placed in 
foster care (Quast, Storch, & Yampolskaya, 2018). Exposure to this type of adversity and 
trauma in childhood are believed to harmfully affect the development of important brain 
systems (Anda et al., 2006), and are subsequently associated with a wide range of adverse 
physical, behavioral, and mental health outcomes in adulthood, including many of the 
leading causes of death (Felitti et al., 1998). Taken together this research suggests that the 
harms of the present opioid include increased childhood exposure to chronic adversity 
and ensuing health problems. 
In addition to these direct impacts on children, if a growing number of children 
are coming into contact with child protection systems because of the opioid epidemic, 
this could strain public child welfare systems capacity to respond to maltreatment writ 
large. Child welfare cases involving substance use tend to be complex and involve 
multiple risk factors. Parents with substance use problems often face other challenges 
such as domestic violence in the home, homelessness, or mental health problems (Patrick 
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& Schiff, 2017). As compared to other child welfare cases, parent substance use is 
overrepresented as a risk factor among child welfare cases that result in removal from the 
home (Barth, 2009). Among those children who are removed, cases involving family 
substance use appear to have longer average times to reunification (Brook, McDonald, 
Gregoire, Press, & Hindman, 2010; Vanderploeg et al., 2007), and may be less likely to 
end in reunification at all (Grella, Needell, Shi, & Hser, 2009). All of this suggests that, 
as the share of child welfare cases involving family substance use increases, so will strain 
on the child welfare system. Indeed, this is precisely what child welfare workers and 
administrators report in qualitative studies (Radel, Baldwin, Crouse, Ghertner, & Waters, 
2018). If this strain grows too severe, it could impact the ability of child welfare agencies 
to adequately care for all children under their purview, both those whose cases involve 
family substance use and others. 
6.1.2 Drug Policy and Child Welfare 
 If, as the evidence presented suggests, the United States’ opioid epidemic is 
increasing risk to children’s safety and health and straining the nation’s child welfare 
system, then it is important to understand whether the public policy response to the 
opioid epidemic is meeting the needs of children and families. Although a number of 
promising practices and policies are described in the introductory chapter, most policies 
recommended by experts do not directly target children and families (Katz, 2018). This 
makes it important to examine broader drug control policies designed to prevent 
addiction in the first place. These policies do not directly target children and families, but 
to the extent that they effectively address some of the root causes of the opioid epidemic, 
may have ancillary benefits for children and families. This paper explores that possibility 
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by examining one such example – Florida’s 2011 crackdown on irresponsible opioid 
prescribing practices. 
6.1.3 Florida Reforms Targeting Opioid Prescribing 
 As described in Chapter 5, from the late 1990s until the end of the 2000s, opioid 
overdose deaths in Florida consistently exceeded the national average (National Institute 
on Drug Abuse, 2018). As a result, Florida adopted a number of reforms to try to reduce 
prescription drug-related mortality. These reforms included establishing a prescription 
drug monitoring program (PDMP), mandating that prescriptions of controlled substances 
be reported to and logged in the PDMP, and mandating that physicians who seek to 
prescribe an opioid to a patient first check the PDMP to review that patient’s prescription 
history (Gau et al., 2017). Reforms also included defining “pain management clinics,” 
requiring those clinics to register with the state, and establishing heightened standards for 
those clinics, including requiring physician ownership, prohibiting operation of onsite 
pharmacies, and requiring that opioid prescribing be accompanied by a medical exam and 
follow-up care (Gau et al., 2017). Following the adoption of these reforms, more than 500 
of Florida’s 900 independent pain management clinics closed (Gau et al., 2017). Opioid 
prescriptions fell as compared to other, similar states, with the largest reductions seen 
among doctors making the highest volume of prescriptions and patients receiving the 
highest volume of prescriptions (Rutkow et al., 2015). As shown both in Chapter 5, and 
by other authors, drug overdose deaths declined as compared to other similar states 
(Kennedy-Hendricks et al., 2016), with a steep decline in oxycodone overdoses in 
particular (Delcher, Wagenaar, Goldberger, Cook, & Maldonado-Molina, 2015). 
6.1.4 Secondary Effects of Florida Policy on Children and Families 
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Taken together, these studies suggest that Florida’s policy changes were, at least 
initially, effective at achieving their primary objective – reducing prescription drug 
overdose. (Overdose deaths in Florida have recently increased dramatically, probably 
because of a spike in deaths from illicit opioids like fentayl (National Institute on Drug 
Abuse, 2018)). In addition, in Chapter 5, we showed these policy changes may have had 
the secondary benefit of reducing motor vehicle crash deaths. Therefore, is important to 
identify if this reduction in opioid-related harms among adults had ancillary benefits by 
causing reductions in child maltreatment and child welfare contacts. On the one hand, we 
might expect a reduction in the opioid supply to lead to fewer parents developing an 
addiction, and consequently having better capacity to care for their children. On the other 
hand, interventions like the PDMP and pill mill laws might mostly benefit populations 
who do not have children, for example older adults with chronic pain, or may be 
inadequate to meet the needs of families using illicit drugs like heroin that are unaffected 
by prescription drug regulations.  
This paper examines whether Florida’s prescription drug monitoring program and 
“pill mill” law reduced the incidence of substantiated abuse and neglect and foster care 
placement relative to what would have occurred in Florida in the absence of these 
policies. Substantiated maltreatment in 12 other states, as well as substantiated 
maltreatment in Florida prior to prescribing reforms, are used to estimate what would 
have occurred in Florida had reforms not been adopted. The effects of policy change are 




 Data come from three sources: 
1. The National Child Abuse and Neglect Data System (NCANDS) is a database of 
all reports of child maltreatment made to state child protection agencies. It is 
maintained by the US Department of Health and Human Services and is 
constructed from data submitted by each individual state. Each record 
corresponds to a report of maltreatment made against a child, and includes 
information on the nature, causes, and outcomes of the report, and the 
demographics of the victim and the perpetrator. Data from the 2002-2016 files 
were used in this analysis. Data are available upon request from the National Data 
Archive on Child Abuse and Neglect (Children’s Bureau, n.d.-b). 
2. The Adoption and Foster Care Analysis and Reporting System (AFCARS) is a 
database of all children placed in foster care by state child protection agencies. 
(Here, foster care refers to any out of home placement, including with kin, in a 
family foster home, in a group home, or in a residential treatment program.) It is 
maintained by the US Department of Health and Human Services and is 
constructed from data submitted by each individual state. Data from the 2002-
2016 files were used in this analysis. Data are available upon request from the 
National Data Archive on Child Abuse and Neglect (Children’s Bureau, n.d.-a). 
3. The U.S. Census maintains annual, intercensal estimates of the population of each 
state under the age of 18. These estimates can be found on the Census bureau’s 
FTP site (https://www2.census.gov/programs-surveys/popest/).  
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Note that the analysis period for the study was Jan 1, 2003 to Dec 31, 2015, but some 
records corresponding to events in 2003 and 2015 were included in files for 2002 and 
2016, respectively. These data were extracted from the 2002 and 2016 files. 
6.2.2 Study Sample 
 The focus of this study is on the effect of Florida’s PDMP and “pill mill” laws on 
child maltreatment. All maltreatment reports between Jan 1, 2003 and December 31, 
2015 are included. Control states were selected based on two criteria. First, states had to 
report data to NCANDS and AFCARS in every year of the analysis. Second states had to 
have some type of PDMP law in place as early as 2002. This restriction was necessary 
because nearly every state that did not have a PDMP in 2002 had established one by the 
end of observation period – this could alter the association between maltreatment in the 
control states and maltreatment in Florida mid-study, violating an assumption of the 
method (see the “Assumptions” section).  After exploratory analysis, Oklahoma and 
Utah, which met both criteria, were further excluded because of large fluctuations in 
substantiated abuse from year to year suggesting a possible reporting error or 
administrative change might have made the data unusable. In the neglect analysis (see the 
“Measures” section), Massachusetts and Illinois were also excluded for the same reason. 
Ultimately, thirteen control states were selected – California, Hawaii, Idaho, Illinois, 
Indiana, Kentucky, Massachusetts, New York, Pennsylvania, Rhode Island, Texas, 
Virginia, and West Virginia.  
6.2.3 Measures 
 The unit of analysis is a state-quarter – the rate of the outcome in a quarter of a 
year (Q1, Jan-Mar; Q2, Apr-Jun; Q3, Jul-Sep; Q4, Oct-Dec) in a particular state.  
 159 
Four outcome measures are examined for all state-quarters between Jan 1, 2002 and 
December 31, 2015: 
6.2.3.1 Physical Abuse Rate. Computed by dividing the number of substantiated 
child abuse incidents reported in a state by the census estimate of the population under 18 
in that state. Note that an incident is counted for each child affected; e.g., an investigation 
of one household with two substantiated abuse victims would contribute two incidents; 
e.g., an investigation of a household with three substantiated abuse victims, and then a 
second substantiated investigation of that same household one month later with three 
substantiated abuse victims, would contribute six incidents. 
6.2.3.2 Sexual Abuse Rate. Computed similarly, but with sexual abuse cases. 
6.2.3.3 Neglect Rate. Computed similarly, but with neglect cases. 
6.2.3.4 Removal Rate. Computed by dividing the number of children placed in 
foster care in a state by the census estimate of the population under 18 in that state.  
Florida’s PDMP began operation at the beginning of 2011, but its “pill mill” went 
into effect on July 1, 2011 (Gau et al., 2017). Therefore, while some intervention effects 
may have begun slightly sooner, in this analysis, all quarters before July 1, 2011 are 
treated as the pre-intervention period, and all quarters July 1, 2011 and later are treated as 
post-intervention. 
6.2.4 Analytic Approach 
 The approach is the same for all measures, so we refer generally to the “child 
welfare contact rate.” The analytic approach is also very similar to Chapter 5 – refer to 
chapter 5 about details and assumptions of BSTS models. 
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The goal of the analysis is to determine how different Florida’s child welfare contact 
rate would have been had it not adopted the opioid prescribing reforms described above 
(hereafter the “intervention”). Bayesian Structural Time Series (BSTS) models were used 
to forecast Florida’s child welfare contact rate in the absence of the intervention. By 
taking the difference between our forecast and the observed rate, we estimate the effect of 
the intervention.  
In this analysis, using BSTS, we average two simple models for Florida’s behavior in 
the post-intervention period:  
3. The first is an AR1 model, where Florida’s child welfare contact rate is forecast 
iteratively as a function of its immediately prior value of the child welfare contact 
rate. (The decision to use an AR1 trend, rather than seasonal model as in Chapter 
5, was based on exploratory analyses of predictive accuracy in control states.) 
4. The second is a “spike-and-slab” linear regression model (Ishwaran & Rao, 
2005), where Florida’s child welfare contact rate in each quarter of the pre-
intervention period is regressed on the contact rate in the comparison states. 
Spike-and-slab regression is a machine-learning approach similar to lasso or ridge 
regression that uses “shrinkage” to down-weight covariates that do less to 
improve predictive accuracy, reducing model variance and improving out-of-
sample predictions as compared a simple linear regression (Ishwaran & Rao, 
2005).  
 To all model parameters – regression coefficients, residual variances, and the 
autoregressive parameter – we assign so-called “non-informative” prior distributions, a 
common default choice in Bayesian analysis. These are consistent with the fact that we 
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have essentially no a priori knowledge about what these parameters should be. In 
addition, the spike-and-slab regression has a meta-parameter that must be chosen – the 
“expected model size” – which was set at 1.  
To estimate the effect of the intervention, we fit a BSTS to forecast Florida’s 
child welfare contact rate in the post-intervention period. For each MCMC iteration, for 
all quarters in the post-intervention period, we take the difference between our forecast 
and the observed value. This produces a full posterior distribution for the effect of the 
intervention at each post-intervention point. In addition, by converting rates into counts 
and taking the cumulative sum from the start of the intervention, we can estimate the 
cumulative change in the number of incidents by each time point as a result of the 
intervention for each MCMC iteration. Taking the mean and 0.025 and 0.975 quantiles of 
these posteriors give point estimates and 95% credible intervals for the effect of the 
intervention at each post-intervention point.  
As before, to test the assumption that any divergence between predicted and 
observed rates are not due to model misspecification, we repeat the same analysis on each 
of the control states, and rank the estimated relative change in number of incidents in 
each state from least in magnitude to greatest in magnitude. Since control states did not 
adopt any intervention, estimated “intervention effects” should be zero in expectation, 
and much less negative than those observed in Florida. misspecification. 




 Trends in child protection involvement in Florida are shown in Table 1. In 
general, substantiated physical and sexual abuse and removals form the home all declined 
and substantiated neglect fluctuated over the study period. 
 Figure 1 shows the physical abuse, sexual abuse, neglect, and removal rates in 
Florida in each quarter of the 13-year period under observation. Superimposed on top are 
the BSTS-based forecast of these rates in the absence of the opioid crackdown. Florida’s 
observed rate falls well within the 95% credible interval for the forecast rate at nearly all 
times for all measures of child maltreatment. Similarly, Figure 2 shows the estimated 
quarterly and cumulative change in the number of maltreatment cases of each type in 
Florida during the 2.5-year intervention period. Estimated changes are small and, for the 
most part, very much within the 95% credible interval of the counterfactual estimates.  
 Table 2 shows the estimated annual percent change in the child welfare contact 
rate, as well as cumulative change in the number of child welfare contacts, at three 
timepoints following the intervention. If Florida’s pill mill law had reduced contact with 
child welfare, we would expect the intervention effect in Florida to be larger than most 
other states – instead, the magnitude of the intervention effect observed in Florida was 
14th  largest out of 14 states for physical abuse (i.e., the smallest effect), 9th out of 14 for 
sexual abuse, 7th out of 12 for neglect, and 9th out of 14 for removals. This suggests 
estimated intervention effects are no larger than would be expected based on chance. 
(Plots comparing Florida to other states are shown in Appendix A).  
6.4. Discussion 
Together, the evidence presented suggests Florida’s opioid prescribing crackdown 
had no appreciable effect on child welfare contact in Florida. Our estimates of the effect 
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of this intervention were much smaller than the uncertainty in our estimates, and 
comparable to the “intervention effects” we estimated in states that did not actually 
implement any intervention. Since these laws had clear effects on problematic opioid 
prescribing and use (Kennedy-Hendricks et al., 2016; Rutkow et al., 2015), and opioid-
related problems in a region clearly linked to both child injury and substantiated 
maltreatment in that region (Ghertner et al., 2018; Wolf et al., 2016), it is worth 
considering why an effective opioid prescribing crackdown had no discernible effect on 
child maltreatment in Florida. At least three possibilities come to mind: First, our data 
come from child protection reports – these reports may be concentrated among families 
struggling with illicit opioids (which are likely unaffected by the policies we reviewed), 
rather than prescription drug misuse. This could be the case if other criminal justice 
involvement related to use of illegal drugs like heroin triggers child protection reports. 
Second, the opioid prescribing crackdown may disproportionately affect adults who are 
not currently caring for dependent children. This could be the case if much of the 
reduction in opioid prescribing was seen in older adults, who make a up disproportionate 
share of high-volume prescription opioid recipients and whose children may be grown 
(Kim, Hartung, Jacob, McCarty, & McConnell, 2016). Third, the impact of an opioid 
prescribing crackdown on child maltreatment might be more delayed than the immediate 
effect of the law on its proximal target – opioid prescribing and overdoses. This would be 
true if the harmful effects of opioid addiction on parenting grow more severe over the 
course of years. Since the uncertainty of our effect estimates is larger at times further 
from the intervention, if the law had benefits in later years, these would be exceedingly 
difficult to detect.   
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It should be noted that a recent working paper by Gihleb and colleagues examined 
a similar question – whether mandating PDMP use causes reductions in foster care entry 
(Gihleb, Giuntella, & Zhang, 2018). That paper also used data from AFCARS. However, 
it reached the opposite conclusion from this dissertation, finding that PDMP laws reduce 
rates of foster care entry. That study differs from the present study in a number of ways. 
Instead of examining the effect of a single state’s intervention, that study attempts to find 
the average effect of adopting a PDMP law by using panel regression to compare trends 
in foster are entry before and after the adoption of PDMP laws. It is possible that, because 
of the particulars of its PDMP law, Florida’s law did not have an impact in child 
maltreatment while other states’ laws did. However, we prefer the approach adopted in 
this study – focusing on an intervention in a single state, and using flexible, semi-
parametric models to forecast counterfactual trends in that state. Focusing on a single 
state avoids the need to impose an equivalence between state laws that appear similar but 
can be quite different in their details or implementation. It also allows for more robust 
model checking, because any effects seen in the intervention state (Florida) can be 
compared to “effects” observed in control states – by contrast, in a panel regression 
where every state is included in the analytic model, there are no intuitive approaches to 
checking for inaccurate forecasts generated by model misspecification. 
This study has a number of limitations. First, most child maltreatment is not 
reported to authorities. Child welfare contact is influenced by many policy decisions – for 
example, mandatory reporting laws, investigative practices, changes in the definition of a 
“substantiated” allegation, or social worker caseloads – other than the true rate of child 
maltreatment. Significant policy changes in any one of the control states might cause the 
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relationship between substantiated maltreatment in those states and Florida to change 
over time, whereas an assumption of our analysis is that, other than the effect of the 
intervention, this association is fixed in time. As noted, we partly address this assumption 
by comparing the estimate of the intervention effect in Florida to the intervention effects 
observed in control states. Second, we used a relatively short pre-intervention period – 
Q1 2003 through Q2 2011, 42 observations – to train our models.  
6.5 Conclusion 
We find no evidence that Florida’s introduction of a PDMP and pill mill law 
reduced child maltreatment. However, we do present a novel method for precise 
estimation of intervention effects following policy change that we hope will be used by 
other child maltreatment researchers. Future research is needed to identify which states or 
policies, if any, are working to effectively reduce the harm to children being caused by 
the opioid epidemic. A comprehensive response to the opioid epidemic must include 
policies that go beyond prevention of the immediate overdose crisis and address the 
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Table 6.1. Quarterly Counts and Rates of Child Welfare Contact Before and After Florida's Opioid Prescribing Crackdown 











January - March, 2003 1678 (4.4) 616 (1.6) 4136 (10.8) 5034 (13.2) 
April -  Jun, 2011 1332 (3.3) 648 (1.6) 7775 (19.5) 4198 (10.5) 
October - December, 2014 1083 (2.7) 563 (1.4) 5789 (14.3) 4038 (10) 
Note: Rate is events per 10,000 children during the three-month period.
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Table 6.2. Estimated Percent Change in Child Welfare Contact following Florida's Opioid Prescribing Crackdown, July 2011-
July 2014 
  July - Sep, 2011 July - Sep, 2012 July - Sep, 2013 July - Sep, 2014 
Physical Abuse     
Annual Percent Change 1.9% (-18.5% to 31.2%) -1.1% (-26.1% to 42.4%) -6.8% (-33.3% to 42.8%) -23.3% (-45.3% to 26.8%) 
Cumulative Percent Change 1.9% (-18.5% to 31.2%) 6.3% (-10.8% to 31.7%) 4.8% (-13.3% to 34.6%) -0.4% (-18.6% to 32.4%) 
Sexual Abuse     
Annual Percent Change 4.9% (-13.8% to 30.9%)  16.9% (-6.9% to 49%) 2.2% (-20.1% to 32.7%) 13.1% (-16.5% to 78.2%) 
Cumulative Percent Change 4.9% (-13.8% to 30.9%)  5% (-10.4% to 21.4%) 4.4% (-11.4% to 20.7%) 5.4% (-11.4% to 23.6%) 
Neglect     
Annual Percent Change 7.6% (-8.7% to 29.5%) -2.9% (-28.3% to 38.8%) -6.5% (-36.5% to 48.1%) -17.9% (-47% to 41.6%) 
Cumulative Percent Change 7.6% (-8.7% to 29.5%) 3.4% (-16.1% to 30.2%) -1.3% (-23.7% to 30.4%) -5% (-29% to 30.9%) 
Foster Care Entry     
Annual Percent Change 7.6% (-8.7% to 29.5%) -2.9% (-28.3% to 38.8%) -6.5% (-36.5% to 48.1%) -17.9% (-47% to 41.6%) 
Cumulative Percent Change 7.6% (-8.7% to 29.5%) 3.4% (-16.1% to 30.2%) -1.3% (-23.7% to 30.4%) -5% (-29% to 30.9%) 
Effects presented as: Estimate (95% Credible Interval)  
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Figure 6.2. Estimated Change in Child Maltreatment Incidents following Florida 
Opioid Prescribing Crackdown 
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Figure 6.1a. Estimated Effect of Florida Opioid Prescribing Crackdown on 








Figure 6.2a. Estimated Effect of Florida Opioid Prescribing Crackdown on 




Figure 6.3a. Estimated Effect of Florida Opioid Prescribing Crackdown on 




Figure 6.4a. Estimated Effect of Florida Opioid Prescribing Crackdown on 









This dissertation examines the United States opioid epidemic’s effect on children. It 
looks at both the childhood experiences of adults currently struggling with opioid misuse, 
the experiences of children growing in households where an adult has an opioid use 
disorder, and the impact of opioid prescription policies on child welfare involvement. 
This program of research is in contrast to most research on the opioid epidemic, which 
has focused on preventing the immediate crisis of adult overdoses. While overdose 
prevention is an urgent and worthy goal, as the research presented here should make 
clear, there is also an urgent public health need to both understand the pediatric causes of 
opioid misuse and address the pediatric consequences of parents’ opioid misuse.  
This dissertation addresses a number of novel questions that contribute to our 
understanding of both the pediatric causes of opioid misuse and pediatric consequences 
of parents’ opioid misuse: 
7.1.1 Aim 1  
7.1.1.1 Goal. Make the first estimate of the number of children growing up in a 
household where an adult has an opioid use disorder. Examine the prevalence of 
substance use treatment utilization among the adults in these households. Examine if 
these adults living with children face unique barriers to care that are less common among 
their counterparts among children. 
7.1.1.2 Findings. There are about 820,000 adults with an opioid use disorder 
living with at least one child. Of these, 28% reported receiving any substance use 
treatment in the past year, a rate comparable to adults not living with a child (30%). 
Among adults reporting unmet treatment need, adults who lived with a child were more 
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likely than adults who did not live with a child to report that 1) access barriers like not 
being able to find the right kind of program and 2) stigma from acquaintances or 
colleagues kept them from receiving care.  
7.1.1.3 Conclusion. There are many children growing up in a household with an 
adult who has an opioid use disorder, and most of these adults are not receiving any 
treatment. While treatment use is similar to adults living without children, expanding 
programs that specifically accommodate the needs of adults living with children and 
using public awareness campaigns to address the stigma of opioid use disorder may be 
important to helping adults with children access needed treatment.  
7.1.2 Aim 2 
 7.1.2.1 Goal. Explores heterogeneity in common trajectories of heroin use over 
the life course of people who have injected drugs. Examine if childhood adversity 
predicts a more severe trajectory of substance use. 
 7.1.2.2 Results. While, on average, the probability of heroin and cocaine use 
declines with age, there is substantial heterogeneity in trajectories of heroin  and cocaine 
use. Some common subtypes of heroin use are people whose heroin use declines sharply 
to zero or near-zero without relapse; people who have a fairly constant, moderate 
probability of using heroin that continues for years; and people who relapse to very high 
probability of use late in life. Further, adverse childhood experiences may explain some 
of this heterogeneity – reporting more than five adverse childhood experiences is 
associated with substantially elevated risk for sustained heroin use into middle-to-late 
adulthood, as compared to people who report fewer than five adverse experience. 
 182 
 7.1.2.3 Conclusions. A history of childhood adversity is associated with 
continuing heroin use into older adulthood, even as peers who used heroin but 
experienced less adversity have stopped using.  This suggests treatment programs that 
address the lasting psychological and physical consequences of childhood trauma may be 
important to meeting the needs of people whose heroin use is chronic and sustained into 
late adulthood. 
7.1.3 Aim 3 
 7.1.3.1 Goal. Given past research showing parent opioid misuse is associated with 
maladaptive parenting and child welfare involvement, test whether a Florida state policy 
to reduce opioid misuse had the ancillary benefit of preventing contact with the child 
welfare system, and develop methods for evaluating similar policies. 
 7.1.3.2 Results. The policy examined was Florida’s reform that cracked down on 
“pill mills” and required physicians to check a prescription drug monitoring program 
(PDMP) before prescribing an opioid. In a preliminary analysis, Bayesian Structural 
Time Series (BSTS) models were used to show overdose deaths declined after the 
introduction of these reforms but suicides did not. In the main analysis, no effect was 
seen on the policy on substantiated incidents of child abuse or neglect, or on rates of 
foster care entry. 
 7.1.3.3 Conclusion. Florida’s pill mill and PDMP are examples of initiatives that 
effectively reduced adult overdose deaths, but do not appear to have reduced any 
potential collateral consequences of the opioid epidemic for children. BSTS models are a 
potentially useful tool for evaluating other opioid-related policies, to test for both 
intended effects on overdose death, and secondary effects on child welfare contact.  
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7.2 Recommendations. 
In combination, these results lend themselves to four recommendations: 
1. Leverage new federal funding opportunities for maltreatment prevention 
to improve collaboration between child welfare, behavioral health, and justice 
systems. The need for improved collaboration between these three systems is made clear 
both by the introductory literature review, and by the novel finding presented here that 
nearly 1 million adults with an opioid use disorder are living with child, but fewer than a 
third receive any treatment. Collaboration between these three systems is required to both 
increase the number of parents with opioid use disorder receiving evidence-based 
treatment, and meet the needs of children while parents are in treatment. For years, these 
treatment programs have been supported on a case-by-case basis using demonstration 
funding from the Children’s Bureau’s “Regional Partnership Grant” program. These 
demonstration programs provide substantial experience that can inform other sites and 
reigions that want to improve inter-agency collaboration around family substance use 
(Stedt & DeCerchio, 2016). Further, beginning in 2019, State costs associated with time-
limited substance use, mental health, and parent training services provided to families 
with a child at risk of entering foster care will, for the first time, be partially reimbursed 
by the federal government (Feder, Letourneau, & Brook, 2018). This new funding offers 
an excellent opportunity for states that have not received regional partnership grants to 
build on the lesson of those grants and improve inter-agency collaboration for families 
with substance use problems.  
2. Prioritize medication-assisted treatment for child welfare involved 
families, and complement this treatment with specialized programs that target the 
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needs of pregnant women and parents. This second recommendation is the major 
positive outcome that should result from the first. Past research has shown that 
medication-assisted treatments are the preferred treatments for opioid use disorder 
generally, and for pregnant and child welfare involved parents specifically (Hall, 
Wilfong, Huebner, Posze, & Willauer, 2016; Patrick & Schiff, 2017). The research in this 
dissertation shows that, despite these benefits, most adults with an opioid use disorder 
who live with a child do not receive any treatment at all. Further, this dissertation finds 
that adults with children are more likely to report they cannot find the kind of program 
that they are looking for than adults without children. This strongly suggests that 
improved collaboration between child welfare and substance use treatment agencies 
should include prioritizing medication-assisted treatment slots for parents, for whom the 
benefits of treatment are double. Further, simply making treatment available is not 
enough – it is likely that the programs parents need include child care and specialty 
services like parent training or programs for domestic violence victims. 
3. Incorporate trauma-informed practices into substance use disorder 
treatment, particularly for chronic or relapsing users. This dissertation shows that 
adults who inject drugs often have a significant history of childhood adversity. Further, it 
shows that among adults who are already using heroin or cocaine, having experienced 
high levels of trauma or adversity in childhood is associated with continuing to use both 
drugs into late adulthood, even as peers with a similar history of drug use stop but less 
childhood adversity using. While we could only study heroin in this paper, there is no 
reason to think the association of childhood adversity with misuse of other opioid drugs 
would be dramatically different. This is valuable information that can should inform the 
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development of new treatments for the most persistent opioid users. In particular, it 
should motivate the adoption of trauma-informed practice in substance use treatment 
programs – the high rates of trauma observed in this study and others suggest trauma-
informed practice needs to be the norm, not just a component of some specialized 
programming. 
4. Rapidly evaluating state opioid policies for secondary effects like changes 
in suicide or child welfare involvement. Finally, this dissertation offers discouraging 
evidence that some policies that are effective at reducing adult overdose deaths are not 
effective at reducing other ancillary harms to children that have been associated with the 
opioid epidemic, like child abuse and foster care involvement. However, it also presents a 
model for how to evaluate opioid-related policies for their effects on children. This 
should be a priority of future research. Over the next several years, states will 
undoubtedly introduce dozens of new policies in an attempt to combat opioid-related 
harms. It will be important to rigorously test not only whether these policies benefit 
adults with opioid use disorder, but also whether they effectively protect children.  
Adoption of these recommendations, and continuing the child-focused research 
introduced in this dissertation, can both help remediate the harms of this epidemic and 
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